Sucampo Pharmaceuticals 10-K 11 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Entity Central Index Key	1,365,216
Trading Symbol	scmp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		45,539,384
Entity Public Float			$ 355.2
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Common Class A [Member]
Stockholders' equity:
Common stock value	$ 455,000	$ 446,000
Common Class B [Member]
Stockholders' equity:
Common stock value	0	0
Cash and cash equivalents	$ 108,284,000	71,622,000
Investments, current		22,393,000
Product royalties receivable	$ 22,792,000	18,576,000
Accounts receivable, net	22,759,000	5,338,000
Deferred charge, current	295,000	295,000
Restricted cash, current	55,218,000	213,000
Inventories, net	33,121,000	0
Prepaid expenses and other current assets	8,891,000	3,411,000
Total current assets	$ 251,360,000	121,848,000
Investments, non-current		13,540,000
Property and equipment, net	$ 6,393,000	763,000
Intangible assets	130,315,000	151,000
Goodwill	60,937,000	$ 0
In-process research & development	$ 6,171,000
Deferred tax assets, non-current		$ 1,047,000
Deferred charge, non-current	$ 1,400,000	1,695,000
Restricted cash, non-current		2,224,000
Other assets	$ 605,000	306,000
Total assets	457,181,000	141,574,000
Accounts payable	11,213,000	4,143,000
Accrued expenses	10,886,000	8,467,000
Deferred revenue, current	676,000	2,051,000
Collaboration obligation	5,623,000	6,000,000
Income tax payable	6,507,000	1,291,000
Notes payable, current	39,083,000	8,240,000
Other current liabilities	14,139,000	3,618,000
Total current liabilities	88,127,000	33,810,000
Notes payable, non-current	213,277,000	17,578,000
Deferred revenue, non-current	1,088,000	5,118,000
Deferred tax liability net, non-current	52,497,000	820,000
Other liabilities	15,743,000	1,936,000
Total liabilities	$ 370,732,000	$ 59,262,000
Commitments and contingencies
Preferred stock, $0.01 par value; 5,000,000 shares authorized at December 31, 2015 and 2014; no shares issued and outstanding at December 31, 2015 and 2014, respectively	$ 0	$ 0
Additional paid-in capital	99,212,000	83,646,000
Accumulated other comprehensive income	13,412,000	14,265,000
Treasury stock, at cost; 3,009,942 and 524,792 shares at December 31, 2015 and 2014, respectively	(46,269,000)	(2,313,000)
Retained earnings (Accumulated deficit)	19,639,000	(13,732,000)
Total stockholders' equity	86,449,000	82,312,000
Total liabilities and stockholders' equity	$ 457,181,000	$ 141,574,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Common Class A [Member]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	270,000,000	270,000,000
Common stock, shares issued (in shares)	45,509,150	44,602,988
Common stock, shares outstanding (in shares)	45,509,150	44,602,988
Common Class B [Member]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury stock, shares (in shares)	3,009,942	524,792

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Product royalty revenue	$ 74,138	$ 62,775	$ 52,100
Product sales revenue	66,276	33,252	16,425
Research and development revenue	10,199	7,246	20,354
Contract and collaboration revenue	$ 2,567	8,817	654
Co-promotion revenue		3,360	61
Total revenues	$ 153,180	115,450	89,594
Costs and expenses:
Costs of goods sold	$ 36,731	16,269	$ 12,402
Intangible assets impairment		5,631
Research and development	$ 33,631	20,566	$ 21,524
General and administrative	35,517	31,230	25,413
Selling and marketing	2,842	14,523	21,059
Total costs and expenses	108,721	88,219	80,398
Income from operations	44,459	27,231	9,196
Non-operating income (expense):
Interest income	181	172	124
Interest expense	(6,854)	(1,520)	(1,894)
Other income, net	5,889	1,250	3,517
Total non-operating income (expense), net	(784)	(98)	1,747
Income before income taxes	43,675	27,133	10,943
Income tax provision	(10,304)	(14,005)	(3,928)
Net income	$ 33,371	$ 13,128	$ 7,015
Net income per share:
Basic (in dollars per share)	$ 0.76	$ 0.30	$ 0.17
Diluted (in dollars per share)	$ 0.73	$ 0.29	$ 0.16
Weighted average common shares outstanding:
Basic (in shares)	44,150	43,691	41,716
Diluted (in shares)	45,680	44,506	42,544
Comprehensive income:
Net income	$ 33,371	$ 13,128	$ 7,015
Other comprehensive income (loss):
Unrealized gain (loss) on pension benefit obligation	105	(978)
Unrealized gain (loss) on investments, net of tax effect	7	(7)	$ 2
Foreign currency translation	(965)	(351)	(567)
Total comprehensive income	$ 32,518	$ 11,792	$ 6,450

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]Common Class A [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2012	41,964,905			457,030
Balance at Dec. 31, 2012	$ 420,000	$ 62,521,000	$ 16,166,000	$ (1,977,000)	$ (33,875,000)	$ 43,255,000
Employee stock option expense		1,744,000				1,744,000
Stock issued upon exercise of stock options (in shares)	597,836
Stock issued upon exercise of stock options	$ 5,000	2,332,000				2,337,000
Stock issued under employee stock purchase plan (in shares)	3,625
Stock issued under employee stock purchase plan		25,000				25,000
Stock issued under "at-the-market" offering (in shares)	749,383
Stock issued under "at-the-market" offering	$ 7,000	5,274,000				5,281,000
Foreign currency translation			(567,000)			(567,000)
Unrealized loss on investments, net of tax effect			2,000			2,000
Windfall tax benefit from stock-based compensation		213,000				213,000
Treasury stock, at cost (in shares)				67,762
Treasury stock, at cost				$ (336,000)		(336,000)
Net income					7,015,000	7,015,000
Balance (in shares) at Dec. 31, 2013	43,315,749			524,792
Balance at Dec. 31, 2013	$ 432,000	72,109,000	15,601,000	$ (2,313,000)	(26,860,000)	$ 58,969,000
Unrealized gain (loss) on pension benefit obligation
Unrealized gain (loss) on investments, net of tax effect			2,000			$ 2,000
Employee stock option expense		2,287,000				$ 2,287,000
Stock issued upon exercise of stock options (in shares)	742,865					618,377
Stock issued upon exercise of stock options	$ 9,000	3,780,000				$ 3,789,000
Stock issued under employee stock purchase plan (in shares)	5,853
Stock issued under employee stock purchase plan		36,000				36,000
Stock issued under "at-the-market" offering (in shares)	538,521
Stock issued under "at-the-market" offering	$ 5,000	5,321,000				5,326,000
Foreign currency translation			(351,000)			(351,000)
Unrealized loss on investments, net of tax effect			(7,000)			(7,000)
Windfall tax benefit from stock-based compensation		113,000				113,000
Net income					13,128,000	13,128,000
Balance (in shares) at Dec. 31, 2014	44,602,988			524,792
Balance at Dec. 31, 2014	$ 446,000	83,646,000	14,265,000	$ (2,313,000)	(13,732,000)	82,312,000
Unrealized gain (loss) on pension benefit obligation			(978,000)			(978,000)
Unrealized gain (loss) on investments, net of tax effect			(7,000)			(7,000)
Employee stock option expense		7,349,000				$ 7,349,000
Stock issued upon exercise of stock options (in shares)	897,077					693,077
Stock issued upon exercise of stock options	$ 9,000	5,614,000				$ 5,623,000
Stock issued under employee stock purchase plan (in shares)	9,085
Stock issued under employee stock purchase plan		128,000				128,000
Foreign currency translation			(965,000)			(965,000)
Unrealized loss on investments, net of tax effect			7,000			7,000
Windfall tax benefit from stock-based compensation		2,475,000				2,475,000
Treasury stock, at cost (in shares)				2,485,150
Treasury stock, at cost				$ (43,956,000)		(43,956,000)
Net income					33,371,000	33,371,000
Balance (in shares) at Dec. 31, 2015	45,509,150			3,009,942
Balance at Dec. 31, 2015	$ 455,000	$ 99,212,000	13,412,000	$ (46,269,000)	$ 19,639,000	86,449,000
Unrealized gain (loss) on pension benefit obligation			105,000			105,000
Unrealized gain (loss) on investments, net of tax effect			$ 7,000			$ 7,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 33,371,000	$ 13,128,000	$ 7,015,000
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	$ 10,580,000	1,090,000	$ 1,488,000
Intangible assets impairment		5,631,000
Deferred tax provision (benefit)	$ (9,779,000)	770,000	$ (1,678,000)
Deferred charge	295,000	3,223,000	673,000
Stock-based compensation	7,349,000	2,287,000	1,744,000
Amortization of premiums on investments	121,000	82,000	110,000
Foreign currency remeasurement gain	(3,687,000)	(1,146,000)	$ (2,023,000)
Shortfall from stock-based compensation	(70,000)	$ (227,000)
Windfall benefit from stock-based compensation	(2,547,000)
Transfer and assignment of licensing rights	(2,000,000)
Changes in operating assets and liabilities:
Accounts receivable	(8,481,000)	$ 67,000	$ (4,047,000)
Unbilled accounts receivable	(668,000)		732,000
Product royalties receivable	(4,216,000)	$ (3,747,000)	(654,000)
Inventory	(1,436,000)	206,000	(163,000)
Income taxes receivable and payable, net	1,110,000	592,000	560,000
Accounts payable	(1,723,000)	(3,437,000)	2,242,000
Accrued expenses	395,000	2,868,000	(4,685,000)
Deferred revenue	(5,351,000)	(191,000)	$ (3,126,000)
Collaboration obligation	(377,000)	6,000,000
Accrued interest payable	(25,000)	(32,000)	$ (32,000)
Other assets and liabilities, net	5,724,000	3,714,000	(2,365,000)
Net cash provided by (used in) operating activities	18,585,000	30,878,000	(4,209,000)
Cash flows from investing activities:
Purchases of investments	(39,775,000)	(29,153,000)	(10,127,000)
Proceeds from the sales of investments	45,062,000	1,700,000	755,000
Maturities of investments	30,554,000	$ 14,650,000	$ 6,485,000
Tenant improvement allowance	(1,880,000)
Purchases of property and equipment	(3,557,000)	$ (66,000)	$ (168,000)
Transfer and assignment of licensing rights	2,000,000
Changes in restricted cash	(2,368,000)	$ 25,828,000	$ (9,561,000)
Acquisition, net of acquired cash	(161,187,000)
Net cash provided by (used in) investing activities	(131,151,000)	$ 12,959,000	$ (12,616,000)
Cash flows from financing activities:
Proceeds from notes payable, net of debt issuance costs	235,911,000		10,600,000
Repayment of notes payable	(8,236,000)	$ (24,904,000)	$ (7,539,000)
Changes in restricted cash	(42,676,000)
Proceeds from exercise of stock options	5,623,000	$ 3,789,000	$ 2,337,000
Proceeds from employee stock purchase plan	$ 128,000	36,000	25,000
Proceeds from "at-the market" stock issuance		$ 5,326,000	5,281,000
Purchase of treasury stock	$ (43,956,000)		(336,000)
Windfall benefit from stock-based compensation	2,547,000	$ 340,000	213,000
Net cash provided by (used in) financing activities	149,341,000	(15,413,000)	10,581,000
Effect of exchange rates on cash and cash equivalents	(113,000)	(904,000)	(1,676,000)
Net increase (decrease) in cash and cash equivalents	36,662,000	27,520,000	(7,920,000)
Cash and cash equivalents at beginning of period	71,622,000	44,102,000	52,022,000
Cash and cash equivalents at end of period	108,284,000	71,622,000	44,102,000
Supplemental cash flow disclosures:
Cash paid for interest	5,983,000	129,000	156,000
Tax refunds received	423,000	76,000	103,000
Tax payments made	$ 17,621,000	$ 9,166,000	$ 4,939,000

Note 1 - Business Organization

Note 1 - Business Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Organization and Basis of Presentation Description of the Business Sucampo Pharmaceuticals, Inc., (Company) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders. The Company currently generates revenue mainly from product royalties, upfront and milestone payments, product sales and reimbursements for development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks additional regulatory approvals and additional indications for approved products and other compounds and seeks strategic opportunities for in-licensing new products. AMITIZA is being marketed for three gastrointestinal indications under the collaboration and license agreement (as amended in October 2014, the North America Takeda Agreement) with Takeda Pharmaceutical Company Limited (Takeda). These indications are chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults suffering from chronic non-cancer related pain. Under the North America Takeda Agreement, the Company is primarily responsible for clinical development activities, while Takeda is responsible for commercialization of AMITIZA in the U.S. and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the U.S. for the treatment of CIC in April 2006, for the treatment of IBS-C in May 2008 and for the treatment of OIC in May 2013. Takeda is required to provide a minimum annual commercial investment during the current term of the North America Takeda Agreement and may reduce the minimum annual commercial investment when a generic equivalent enters the market. In October 2015, Health Canada approved AMITIZA for CIC in adults. In October 2014, the Company and Takeda executed amendments (Takeda Amendment) to the North America Takeda Agreement which, among other things, extended the term of the North America Takeda Agreement beyond December 2020. During the extended term, Takeda and the Company will split the annual net sales revenue of the branded AMITIZA products. In addition, beginning April 2015, the North America Takeda Agreement was amended to terminate the Company’s right to perform commercialization activities with respect to AMITIZA and Takeda’s obligation to reimburse the Company for such commercialization activities. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement (the Japan Mylan Agreement) that was transferred to Mylan, Inc. (Mylan) from Abbott Laboratories, Inc. (Abbott), as of February 2015, as part of Mylan’s acquisition of a product portfolio from Abbott. The Company received approval of its new drug application (NDA) for AMITIZA for the treatment of chronic constipation (CC), excluding constipation caused by organic diseases, from the Ministry of Health, Labour and Welfare in June 2012 and pricing approval in November 2012. AMITIZA is Japan’s only prescription medicine for CC. The Company did not experience any significant changes in the commercialization of AMITIZA in Japan as a result of the transfer of the Japan Mylan Agreement from Abbott to Mylan. In the People’s Republic of China, the Company entered into an exclusive license, development, commercialization and supply agreement (the China Gloria Agreement) with Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria), for AMITIZA in May 2015. Under the China Gloria Agreement, Gloria is responsible for all development activities and costs, as well as commercialization and regulatory activities, for AMITIZA in the People’s Republic of China. The Company will be the exclusive supplier of AMITIZA to Gloria at an agreed upon supply price. Upon entering into the China Gloria Agreement, the Company received an upfront payment of $1.0 million. In June 2015, the China Food and Drug Administration accepted an Investigational New Drug (IND) application for a pivotal trial of AMITIZA in patients with CIC; as a result the Company received an additional payment of $500,000 from Gloria. In addition to the $1.5 million in payments received and recognized as revenue through June 2015, the Company is eligible to receive an additional payment in the amount of $1.5 million upon the occurrence of a specified regulatory or commercial milestone event. In October 2014, the Company entered into an exclusive license, development, commercialization and supply agreement (the Global Takeda Agreement) for lubiprostone with Takeda, through which Takeda has the exclusive rights to further develop and commercialize AMITIZA in all global markets, except the U.S., Canada, Japan and the People’s Republic of China. Takeda became the marketing authorization holder in Switzerland in April 2015 and is expected to become the marketing authorization holder in the United Kingdom (U.K.), Austria, Belgium, Germany, Italy, Ireland, Luxembourg, the Netherlands and Spain in the first half of 2016. Before the execution of the Global Takeda Agreement, the Company retained full rights to develop and commercialize AMITIZA for the rest of the world’s markets outside of the U.S., Canada and Japan. In the U.K., the Company received approval in September 2012 from the Medicines and Healthcare Products Regulatory Agency (MHRA) for the use of AMITIZA to treat CIC. The Company made AMITIZA available in the U.K. in the fourth quarter of 2013. In 2014, the Company resubmitted an application to the MHRA for approval of the OIC indication following its initial decision to not approve in March 2014. In January 2016, the Company received notification from the MHRA that the appeal for the OIC indication was not approved. The Company will not pursue additional filings in the U.K. at this time. In July 2014, National Institute of Health and Care Excellence (NICE) published the technology appraisal guidance recommending the use of AMITIZA in the treatment of CIC and associated symptoms in adults who have failed laxatives. In January 2015, the Company successfully completed the European mutual recognition procedure (MRP) for AMITIZA for the treatment of CIC in select European countries, resulting in a recommendation for marketing authorization. In Switzerland, AMITIZA was approved to treat CIC in 2009. In 2012, the Company reached an agreement with the Bundesamt fur Gesundheit, (BAG), the Federal Office of Public Health in Switzerland, on a reimbursement price for AMITIZA in Switzerland, and began active marketing in the first quarter of 2013. Since February 2012, AMITIZA has also been available through a Named Patient Program throughout the European Union, Iceland and Norway. In February 2014, the Company announced that the BAG revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Spezialitätenliste (SL) to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine month period. In July 2014, AMITIZA was approved for the treatment of OIC in chronic, non-cancer adult patients by the Swissmedic, the Swiss Agency for Therapeutic Products. In October 2015, the Company and Takeda obtained approval of the clinical trial application (CTA) for AMITIZA for the treatment of CIC and IBS-C in Russia that was submitted in June 2015. In December 2015, a CTA was filed for AMITIZA for the treatment of CIC, IBS-C and OIC in Mexico and South Korea. The Company expects to initiate phase 3 registration trials in Russia, Mexico, and South Korea in the first half of 2016. An NDA for the treatment of CIC, IBS-C, and OIC was submitted in Kazakhstan in December 2015. In the U.S., the Company ceased marketing RESCULA in the fourth quarter of 2014 and no product was made available after the March 2015 expiration date. In May 2015, the Company returned all licenses for unoprostone isopropyl to R-Tech. As part of the acquisition of R-Tech in October 2015, the Company acquired all rights to RESCULA. RESCULA is being commercialized by Santen Pharmaceutical Co., Ltd in Japan, Dong-A Pharmaceutical, Co., Ltd in South Korea and Zuelliq Pharma Co., Ltd in Taiwan. The Company’s other clinical development programs include the following: Lubiprostone Alternate Formulation The Company has been developing an alternate formulation of lubiprostone for both adult and pediatric patients who are unable to tolerate capsules and for naso-gastric tube fed patients. Takeda has agreed to fund 100% of the costs, up to a cap, of this alternate formulation work and the Company expects to initiate a phase 3 trial of the alternate formulation of lubiprostone in the second half of 2016. Lubiprostone for Pediatric Functional Constipation The phase 3 program required to support an application for marketing approval of lubiprostone for pediatric functional constipation comprises four clinical trials, two of which are currently ongoing and are both testing the soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age. The first of the two trials is a pivotal 12-week, randomized, placebo-controlled trial which was initiated in December 2013. The second trial is a follow-on, long-term safety extension trial that was initiated in March 2014. Following the successful completion of the phase 3 trial for the alternative formulation of lubiprostone, as described above, the Company is also planning to initiate two additional trials in its phase 3 program for pediatric functional constipation, which will be in children aged 6 months to less than 6 years testing the alternative formulation. Takeda has agreed to fund 70% of the costs, up to a cap, of this pediatric functional constipation program. Cobiprostone for Oral Mucositis In May 2015, the U.S. FDA granted Fast Track Designation for cobiprostone for the prevention of OM. In September 2015, the Company initiated a phase 2a clinical trial in the U.S. of cobiprostone oral spray for the prevention of OM in patients suffering from HNC receiving concurrent RT and CT. Cobiprostone for Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease (NERD)/symptomatic Gastroesophageal Reflux Disease (sGERD) In December 2014, the Company initiated a phase 2a clinical trial in Japan for cobiprostone in NERD/sGERD patients who have had a non-satisfactory response to proton pump inhibitors. The Company expects to announce top-line data from this study in the first half of 2016. VAP-1 Inhibitor for RTU-1096 RTU-1096 is an oral compound under development for the treatment of nonalcoholic steatohepatitis (NASH), chronic obstructive pulmonary disease (COPD), diabetic macular edema (DME) and diabetic retinopathy (DR) and immune-oncology. In the first quarter of 2016, the phase 1 trial has been completed in healthy individuals that evaluated the safety and pharmacokinetics and the results will be accessed in the first half of 2016. The Company will also look to generate additional preclinical data in the emerging area of immune-oncology, to support partnership opportunities of combination therapy in cancer patients of our molecules with check-point pathway inhibitors. VAP-1 Inhibitor for RTU-009 RTU-009 is a pre-clinical stage, injectable VAP-1 inhibitor that is being studied in acute cerebral infarction as well as ophthalmic diseases. Our next step would be to complete IND-enabling studies, and thereafter initiate clinical-stage development. Basis of Presentation The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America, (GAAP) and the rules and regulations of the Securities and Exchange Commission, (SEC). The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd. (acquired October 20, 2015), based in Kobe, Japan through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America and Sucampo Pharma Europe, Ltd., based in Oxford, U.K.. All inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Sucampo Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expense during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For the purpose of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase. Current and Non-Current Investments Current and non-current investments consist primarily of U.S. government agency securities, certificates of deposit, corporate bonds, municipal securities and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available-for-sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income. Accounts Receivable Accounts receivable primarily represents amounts due under the North America Takeda Agreement and Japan Mylan Agreement. The Company recorded an immaterial allowance for doubtful accounts at December 31, 2015 and 2014. Accounts receivable of zero and $779,000 were charged off against the allowance for doubtful accounts during the years ended December 31, 2015 and 2014, respectively. Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out convention. Inventories consist of raw material, work-in-process and finished goods. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. Restricted Cash As of December 31, 2015, restricted cash consisted primarily of $25.0 million related to the Credit Facility that requires the Company to maintain $25.0 million in a restricted cash account until at least $35 million of the Term Loans have been repaid or prepaid (see note 17). Further, as part of the R-Tech acquisition, $17.7 million is held in a restricted cash account for payment of the Ueno and Kuno Trust Notes, which were settled on February 1, 2016 (see note 17), and $8.2 million is held in restricted cash related to the squeeze out of non-tendering R-Tech shareholders, which was settled in January, 2016. Restricted cash at December 31, 2014 primarily represented collateral pledged to support a loan guarantee and development agreement (Numab Agreement) between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled $2.4 million at December 31, 2014. Property and Equipment Property and equipment are recorded at cost and consist of computer and office machines, furniture and fixtures, IT infrastructure and leasehold improvements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in earnings. Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of December 31, 2015 and 2014, approximately $5.9 million, or 3.6%, and $37.0 million, or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or other government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 63.3%, 71.3% and 81.3% of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013, respectively. Accounts receivable and product royalties receivable from Takeda accounted for 78.1% and 88.5% of the Company’s total accounts receivable and product royalties receivable at December 31, 2015 and 2014. Revenues from another unrelated party, Mylan, accounted for 35.2%, 27.8% and 17.6% of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013. The Company depends significantly upon collaborations with Takeda and Mylan, and its activities may be impacted if these relationships are disrupted (see note 19). Fair Value of Financial Instruments The carrying values of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable, collaboration obligation and accrued expenses. The carrying amounts of the Notes (as defined below) at December 31, 2015 and 2014 did approximate fair value and are classified as a Level 2 instrument. Revenue Recognition The Company’s revenues are derived primarily from product royalties, product sales, development milestone payments, clinical development activities, and contract and collaboration activities. Multiple-Element Arrangements The Company evaluated the multiple deliverables within the AMITIZA agreements in accordance with the guidance of multiple deliverables under ASC 605-25 “ Revenue Recognition — Multiple-Element Arrangements” Where agreements include contingent milestones the Company evaluates whether each milestone is substantive. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Where milestones are not considered substantive their treatment is based on either a time-based or proportional performance model. Research and Development Revenue The Company applied a time-based model of revenue recognition for cash flows associated with research and development deliverables agreed upon prior to January 1, 2011 under the North America Takeda Agreement. Under this model, cash flow streams related to each unit of accounting are recognized as revenue over the estimated performance period. Upon receipt of cash payments, such as development milestones, revenue is recognized to the extent the accumulated service time has occurred. The remainder is deferred and recognized as revenue ratably over the remaining estimated performance period. For research and development deliverables agreed upon subsequent to January 1, 2011 under the North America Takeda agreement, which are reimbursable by Takeda at contractually predetermined percentages, the Company recognizes revenue when the underlying research and development expenses are incurred, assuming all other revenue recognition criteria are met. Product Royalty Revenue Product royalty revenue represents royalty revenue earned on Takeda’s net sales of AMITIZA under the North America Takeda Agreement, and is recorded when earned in accordance with the contractual terms, collectability is reasonably assured and all other revenue recognition criteria are met. Product Sales Revenue Product sales revenue consists of AMITIZA sales under the Japan Mylan Agreement, the North America Takeda Agreement, Global Takeda Agreement, and prior to the Global Takeda Agreement, by the Company in Europe, and RESCULA sales to Santen in Japan and by the Company in the U.S. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return. Co-promotion Revenue Takeda reimbursements of co-promotion costs under the North America Takeda Agreement, including costs associated with the Company’s specialty sales force and miscellaneous marketing activities, are recognized as co-promotion revenue as the related costs are incurred and Takeda becomes contractually obligated to pay the amounts. The Company has determined that it is acting as a principal under this agreement, and as such, records reimbursements of these amounts on a gross basis as co-promotion revenue. In December 2014, the Company ceased co-promoting AMITIZA as a result of the amendment to the North America Takeda Agreement. Contract and Collaboration Revenue Contract and Collaboration revenue relates to development and consulting activities and includes $8.0 million of the upfront payment received from Takeda in 2014 under the Global Takeda Agreement. The Company considers its participation in joint committees under the Japan Mylan Agreement and North America Takeda Agreement as separate deliverables under the contracts and recognizes the best estimate of selling price of such participation as collaboration revenue over the period of the participation per the terms of the contracts. Deferred Revenue Deferred revenue represents payments received for licensing fees, option fees, consulting, research and development contracts and related cost sharing and supply agreements, mainly with Takeda and Mylan, which are deferred until revenue can be recognized under the Company’s revenue recognition policy. At December 31, 2015 and 2014, total deferred revenue was approximately $1.8 million and $7.2 million, respectively. Total deferred revenue consists of the following as of: December 31, (In thousands) 2015 2014 Deferred revenue, current $ 676 $ 2,051 Deferred revenue, non-current 1,088 5,118 $ 1,764 $ 7,169 Deferred revenue to related parties, included in total deferred revenue: Deferred revenue to related parties, current $ - $ 453 Deferred revenue to related parties, non-current - 4,141 Total $ - $ 4,594 During the fourth quarter of 2015, as part of the R-Tech acquisition, the Company recognized $3.9 million of deferred revenue as part of settlement of a pre-existing relationship with R-Tech. Stock-Based Compensation The Company estimates the fair value of share-based payment awards on the date of the grant using an option-pricing model and recognizes the expense over the required service periods. For recording of the stock-based compensation expense for service based and market condition options, the Company has chosen to use: · the straight-line method of allocating compensation cost for service based options and graded vesting for market condition options; · the Black-Scholes-Merton option pricing formula for time based options and the Monte Carlo simulation model for the market condition options as the Company’s chosen option-pricing models; · the simplified method to calculate the expected term for options as discussed under the SEC’s guidance for share-based payments for service based options; · an estimate of expected volatility based on the historical volatility of the Company’s share price; and · an estimate for expected forfeitures. The three factors which most affect stock-based compensation are the fair value of the common stock underlying the stock options, the vesting term of the options, and the volatility of such fair value of the underlying common stock. If the Company’s estimates are too high or too low, the Company may overstate or understate its stock-based compensation expense. Pension The Company utilizes actuarial methods to measure the benefit obligations and net periodic pension cost/income for its Swiss pension plan. Inherent in the application of these actuarial methods are key assumptions, including, but not limited to, discount rates, mortality rates, and rates of compensation increases. Company management evaluates these assumptions annually and updates assumptions as necessary. Net actuarial gains or losses are amortized to expense in future periods over the average future service period for employees of plans. The fair values of assets are determined based on the sum of the saving capitals of the actives in the pension plan. Mergers and Acquisitions In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the merger or acquisition at their respective fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect our intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of the merger or acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. The fair values of intangible assets, including acquired in-process research and development (IPR&D) are determined utilizing information available near the merger or acquisition date based on expectations and assumptions of a market participant that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Amounts allocated to acquire IPR&D are capitalized and accounted for as indefinite-lived intangible assets. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company's results of operations. The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an "income approach" through which fair value is estimated based on each asset's discounted projected net cash flows. Our estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company's competitors; and the life of each asset's underlying patent, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate. The fair values of identifiable intangible assets related to IPR&D are determined using an income or cost approach. Under the income approach fair value is estimated based on each asset’s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using appropriate discounts. Under the replacement cost approach, historical research and development spending is analyzed to derive the costs incurred to date related to the asset. An expected return of 20% was applied to the cumulative research and development costs incurred to date, as this estimates the required rate of a return a prudent investor would require on a similarly situated asset. No tax amortization benefit is applied given the asset is valued under the replacement cost approach, which is representative of buying the asset in the market at fair value. Goodwill The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recognized. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital. The Company also evaluates goodwill using the qualitative assessment method, which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected the fair value of the reporting unit since the date of the most recent quantitative analysis of a reporting unit's fair value. As described in note 4 to these consolidated financial statements, the Company operates as one operating segment which is considered our only reporting unit. The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1 as its annual impairment test date. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses from third parties who conduct research and development activities pursuant to development and consulting agreements on behalf of the Company. Costs related to the acquisition of intellectual property are expensed as incurred in research and development expenses since the underlying technology associated with such acquisitions is unproven, has not received regulatory approval at its early stage of development and does not have alternative future uses. Milestone payments due under agreements with third party contract research organizations (CROs) are accrued when it is considered probable that the milestone event will be achieved. Accrued Research and Development Expenses As part of the process of preparing Consolidated Financial Statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company’s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external CROs and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment; invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes significant judgments and estimates in determining the accrued balance in any accounting period. No material adjustments have been required for this accrual during the years ended December 31, 2015 and 2014. Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with the relevant accounting guidance for income taxes. Under the asset and liability method, the current income tax provision or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in the income tax provision during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carry-forwards that can be utilized in the future to offset taxable income. The Company’s discussion of income tax is described more fully under note 21 found below. In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the U.S. based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. As of December 31, 2015, 2014 and 2013, the total deferred charge is $1.7 million, $2.0 million and $5.2 million, respectively, after a net current year amortization and impairment expense of $0.3 million, $3.2 million and $0.7 million, respectively. Impairment expense included in the $3.2 million for 2014 totaled $1.8 million and resulted from the cessation of direct commercialization activities for RESCULA in 2014. For all significant intercompany transactions, the Company’s management has evaluated the terms of the transactions using significant estimates and judgments to ensure that each significant transaction would be on similar terms if the Company completed the transaction with an unrelated party. Although the Company believes there will be no material tax liabilities to the Company as a result of multi-jurisdictional transactions, there can be no assurance that taxing authorities will not assert that transactions were entered into at monetary values other than fair values. If such assertions were made, the Company’s intention would be to vigorously defend its positions; however, there can be no assurance that additional liabilities may not occur as a result of any such assertions. The Company considers certain undistributed earnings of foreign subsidiaries to be indefinitely reinvested outside of the U.S. and, accordingly, no U.S. deferred taxes have been recorded under the applicable accounting standard with respect to such earnings. Should the earnings be remitted to the U.S., the Company may be subject to additional U.S. taxes, net of allowable foreign tax credits. It is not practicable to estimate the amount of any additional taxes which may be payable on the undistributed earnings. Uncertain Tax Positions The Company applies the accounting guidance for uncertain tax positions that requires the application of a more likely than not threshold to the recognition and de-recognition of uncertain tax positions. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement. The Company has recorded an income tax liability of approximately $2.9 million and $0.8 million, including interest, for uncertain tax positions as of December 31, 2015 and 2014, respectively. As of December 31, 2015, the entire balance was reflected as other liabilities in the accompanying Consolidated Balance Sheets. As of December 31, 2014, $0.3 million and $0.6 million are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. These amounts represent the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. It is reasonably possible that the $1.3 million of the liability for unrecognized tax benefits will decrease within the next 12 months. In addition, future changes in the unrecognized tax benefits would have an effect on the effective tax rate when recognized. Currently, tax years 2011 to 2015 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed. Foreign Currency The functional currency for most of the Company’s foreign subsidiaries is its local currency. For the Company’s non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency is the U.S. dollar, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in net income. Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income. Other Comprehensive Income Comprehensive income consists of net income plus certain other items that are recorded directly to stockholders’ equity. The Company has reported comprehensive income in the Consolidated Statements of Operations and Comprehensive Income. The Company has outstanding intercompany loans and investments between its subsidiaries which are eliminated for purposes of the Consolidated Financial Statements. These intercompany loans are not expected to be repaid or settled in the foreseeable future. Accordingly, the currency transaction gains or losses on these intercompany loans are recorded as part of other comprehensive income in the Consolidated Financial Statements. In addition, the actuarial gains and losses of the Swiss Pension plan are recorded in comprehensive income. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued new guidance related to accounting for leases. The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. For leases with a term of 12 months or less, a lessee can make an accounting policy election by class of underlying asset to not recognize an asset and corresponding liability. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. These disclosures are intended to supplement the amounts recorded in the financial statements and provide additional information about the nature of an organization’s leasing activities. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The transition guidance also provides specific guidance for sale and leaseback transactions, build-to-suit leases and amounts previously recognized in accordance with the business combinations guidance for leases. We are currently evaluating our expected adoption method and the impact of this new standard on our consolidated financial statements. In January 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In September 2015, the FASB issued Accounting Standards Update 2015-16, Business Combinations (Topic 805) - Simplifying the Accounting for Measurement-Period Adjustments In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In April 2015 Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 will have no effect on the Company’s results of operations or liquidity. In May 2014, the FASB issued authoritative guidance which sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance was originally scheduled to be effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, but in July 2015 the FASB voted to defer the effective date to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date of December 15, 2016. Companies may use e

Note 3 - Net Income Per Share

Note 3 - Net Income Per Share	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Net Income per Share Basic net income per share is computed by dividing net income by the sum of the weighted average class A and class B common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share. The computation of net income per share for the years ended December 31, 2015, 2014 and 2013 is shown below: Year To Date December 31, (in thousands, except per share data) 2015 2014 2013 Basic net income per share: Net income $ 33,371 $ 13,128 $ 7,015 Weighted average class A and B common shares outstanding 44,150 43,691 41,716 Basic net income per share $ 0.76 $ 0.30 $ 0.17 Diluted net income per share: Net income $ 33,371 $ 13,128 $ 7,015 Weighted average class A and B common shares outstanding for diluted net income per share 44,150 43,691 41,716 Assumed exercise of stock options under the treasury stock method 1,530 815 828 45,680 44,506 42,544 Diluted net income per share $ 0.73 $ 0.29 $ 0.16 The potentially dilutive securities used in the calculations of diluted net income per share at December 31, 2015, 2014 and 2013 are as follows: December 31, (In thousands) 2015 2014 2013 Employee stock options 3,290 1,124 2,129 Non-employee stock options - 255 410 The following securities were excluded from the computation of diluted net income per share as their effect would be anti-dilutive as of December 31, 2015, 2014 and 2013: December 31, (In thousands) 2015 2014 2013 Employee stock options 1,188 3,012 530

Note 4 - Segment Reporting

Note 4 - Segment Reporting	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	4. Segment Information In the first quarter of 2015, the Company made a number of strategic and operational changes to its business, including re-evaluating and accelerating its pipeline to focus on clinical programs that it believes hold the most promise for patients, the highest likelihood for regulatory approval, and the strongest potential for commercial return. As a result of such changes, the Company combined its reportable geographic segments of Asia, the Americas and Europe into one operating segment: the development and commercialization of pharmaceutical products. This change reflects the manner in which information is now being presented internally and used by the Company’s chief operating decision maker, the Company’s Chief Executive Officer, to allocate resources and assess performance. Summarized product category and geographic information is shown in the tables below. Product Category Information Revenues for product categories are attributed based on the following categories. Product royalty revenue represents royalty revenue earned on the net sales of AMITIZA in North America. Product sales revenue represents drug product net sales of AMITIZA in North America, Japan and Europe and drug product net sales of RESCULA in Japan. Research and development revenue represents funded development work primarily related to AMITIZA. Contract and collaboration revenue represents the amortization of up-front payments under the North America Takeda Agreement and release of the collaboration obligation under the Global Takeda agreement. Co-promotion revenue represents reimbursements by Takeda of a portion of the Company’s co-promotion costs for its specialty sales force. Company revenues by product category for the years ended December 31, 2015, 2014 and 2013 were as follows: Years Ended December 31, (In thousands) 2015 2014 2013 Product royalty revenue $ 74,138 $ 62,775 $ 52,100 Product sales revenue 66,276 33,252 16,425 Research and development revenue 10,199 7,246 654 Contract and collaboration revenue 2,567 8,817 20,354 Co-promotion revenue - 3,360 61 Total $ 153,180 $ 115,450 $ 89,594 Geographical Information Revenues are attributable to countries based on the location of the customer. The Company operates a manufacturing facility in Japan that supplies products to customers as well as the Company’s subsidiaries in other countries. The sales from the manufacturing operations to other countries are included in the net sales of the country in which the manufacturing location is based. The intersegment portions of such sales are excluded to derive consolidated revenues. The Company’s country of domicile is the United States. Company revenues by geographic location for the years ended December 31, 2015, 2014 and 2013 were as follows: Years Ended December 31, (In thousands) 2015 2014 2013 United States $ 95,769 $ 74,688 $ 73,637 Japan 55,371 32,128 15,849 Rest of the world 2,040 8,634 108 Total $ 153,180 $ 115,450 $ 89,594 The Company’s long-lived assets by geographic location where located on December 31, 2015, 2014 and 2013 were as follows: December 31, (In thousands) 2015 2014 2013 United States $ 3,105 $ 566 $ 869 Japan 3,232 114 175 Rest of the world 56 83 112 Total $ 6,393 $ 763 $ 1,156

Note 5 - Acquisitions

Note 5 - Acquisitions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]	5. Acquisitions Acquisitions have been accounted for as business combinations and the acquired companies results have been included in the accompanying consolidated statements of income from their respective date of acquisition. Acquisition of R-Tech In August 2015, the Company entered into a share purchase agreement with Drs. Ryuji Ueno and Sachiko Kuno and S&R Technology Holdings, LLC, to acquire 44% of outstanding R-Tech shares. The total purchase price for these shares was 1,400 Japanese Yen (JPY) per share, or 12 billion JPY in the aggregate, or approximately $100.0 million. In August 2015, the Company launched, through its wholly-owned Japanese subsidiary (the Offeror), an all-cash tender offer in Japan to acquire the remaining 56% of the outstanding shares and stock acquisition rights of R-Tech for 1,900 JPY per share, resulting in a total consideration of up to 21 billion JPY, or approximately $175.0 million. The price offered in the tender offer reflected that R-Tech held approximately $62.1 million in cash and 2.5 million shares of the Company’s common stock as of the commencement of the tender offer. On October 20, 2015, the transactions contemplated by the share purchase agreement were completed, and the tender offer was concluded. As a result of these transactions, the Company acquired approximately 98% of R-Tech’s outstanding shares. The Company acquired the remaining 2% of outstanding shares of R-Tech through a squeeze-out process under Japanese law on December 8, 2015 for total consideration of 926 million JPY, or approximately $7.7 million. This acquisition diversified the product portfolio, expanded the Company’s development pipeline and integrated the manufacturing of the Company’s main product, AMITIZA. This transaction was accounted for under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of R-Tech were recorded as of the acquisition date at their respective fair values, and combined with those of the Company. The allocation of the purchase price is preliminary and is not yet finalized. The purchase price allocation is still considered preliminary due to finalization of valuation reports, evaluation of acquired tax attributes and review of IPR&D. The preliminary allocation of the purchase price is based upon preliminary estimates using information that was available to management at the time the financial statements were prepared and these estimates and assumptions are subject to change within the measurement period, up to one year form the acquisition date. Accordingly, the allocation may change. The Company continues to gather information about the fair value of all assets and liabilities, including intangible assets, acquired deferred tax and liabilities. Acquisition related costs are expensed when incurred and are included in general and administrative expenses in the consolidated statement of operations and comprehensive income. The preliminary allocation of the purchase price based upon estimated fair value of assets acquired and liabilities assumed on October 20, 2015 is as follows: (In thousands) As of October 20, 2015 Cash $ 62,097 Accounts receivable 8,299 Inventory (i) 37,563 Prepaid expenses 3,425 Property, plant and equipment 3,115 Other long term assets 449 Accounts payable and accrued liabilities (11,598 ) Income tax payable (5,025 ) Other liabilities, current (3,282 ) Deferred tax liability, net (62,927 ) Other liabilities, long term (9,347 ) R-Tech shares of Sucampo stock (treasury stock) 43,956 Total fair value of tangible assets acquired and liabilities assumed 66,725 Acquired in-process research and development 6,200 Acquired intangible assets 134,600 Goodwill 61,228 Total purchase price $ 268,753 Total purchase price $ 268,753 Settlement of net receivable from pre-existing relationship 6,364 Total consideration $ 275,117 Acquisition, net of acquired cash $ 161,187 Acquired cash 62,097 Purchase of treasury stock 43,956 Squeeze out liability for non-tendering R-Tech shareholders 7,668 Other 209 Total consideration $ 275,117 (i) Acquired inventory includes a $20.1 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $20.1 million step-up adjustment will amortize evenly through costs of goods sold over a seven month period beginning in November 2015 and ending in May 2016, in alignment with expected inventory turnover. The amortization of the inventory step-up adjustment will increase costs of goods sold during these periods. For the year ended December 31, 2015, the Company recognized $5.8 million in additional costs of goods sold related to the amortization of the inventory step-up adjustment. The estimated fair value of intangible assets acquired and related estimated amortization periods in years is as follows: (In thousands) As of October Amortization Acquired in-process research and development $ 6,200 Indefinite Acquired intangible assets: AMITIZA - manufacturing know-how 120,200 14 RESCULA - manufacturing know-how 14,400 10 $ 134,600 In-process research and development (IPR&D) acquired from R-Tech is related to RTU-009 and RTU-1096. Management estimated the fair value of IPR&D at the acquisition date to be $6.2 million. The estimated fair value was determined using the replacement cost approach. Under the replacement cost approach, historical research and development spending is analyzed to derive the costs incurred to date related to the asset. An expected return of 20% was applied to the cumulative mid-year pre-tax research and development costs incurred to date, as this estimates the required rate of a return a prudent investor would require on a similarly situated asset. An adjustment was not made for economic obsolescence as the costs considered are historical and the method applied is considering the estimate of fair value to buy the asset in the market at its current stage of development. No tax amortization benefit has been applied given the asset is valued under the replacement cost approach, which is representative of buying the asset in the market at fair trade value. The Company estimated the fair values of the AMITIZA manufacturing know-how intangible asset and RESCULA manufacturing know-how intangible asset using the income approach with a present value discount rate of 18%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of R-Tech and the Company. This is comparable to the estimated internal rate of return for the acquisition and presents the rate that market participants would use to value these intangible assets. The projected cash flows from the AMITIZA manufacturing know-how intangible asset and RESCULA manufacturing know-how intangible asset were based on key assumptions including estimates of revenues, operating profits, the life of the potential commercialized product, associated risks, and the risks related to the viability of and potential alternative use in any future markets. The weighted average amortization period of the intangible assets from the R-Tech acquisition is 78 months which is reflective of expected cash flows. For the year ended December 31, 2015, the Company recorded amortization expense of $3.7 million, all of which has been recorded in costs of goods sold in the Consolidated Statements of Operations and Comprehensive Income. The Company recorded approximately $61.2 million in goodwill related to the acquisition of R-Tech, representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. None of the goodwill generated from R-Tech acquisition is expected to be deductible for tax purposes. The Company has incurred transaction costs related to the R-Tech acquisition of approximately $5.2 million for the year ended December 31, 2015, all of which has been recorded in general and administrative expenses. The following unaudited pro forma information is presented as if the acquisition had occurred on January 1, 2014, and combines the historical results of operations of the Company and R-Tech for the year ended December 31, 2015 and 2014. Year Ended December 31, (In thousands) 2015 2014 Pro forma revenue $ 199,462 $ 151,527 Pro forma net income 25,617 (20,031 ) For the year ended December 31, 2015, R-Tech contributed revenues and net loss to the Company’s consolidated results of $11.8 million and $4.7 million, respectively.

Note 6 - Restructuring

Note 6 - Restructuring	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	6. Restructuring In December 2015, the Company adopted a plan to restructure certain operations and consolidate certain functions in the Company’s corporate headquarters located in Rockville, Maryland. During the fourth quarter, the Company recorded pretax charges of approximately $953,000. The restructuring plan primarily included headcount reductions. These costs are reflected within operating expenses between research and development, general and administrative expenses, and selling and marketing expenses. At December 31, 2015, a restructuring accrual of $851,000 was included in accrued liabilities. The Company expects to record additional restructuring charges in 2016 related to this program and in connection with the integration of the R-Tech acquisition. The following table summarizes the cash components of the restructuring costs at December 31, 2015. (In thousands) Termination Facility Contract & Total Balance at December 31, 2014 $ - $ - $ - $ - Expenses incurred 953 - - 953 Amounts paid (102 ) - - (102 ) Balance at December 31, 2015 $ 851 $ - $ - $ 851

Note 7 - Current and Non-Curren

Note 7 - Current and Non-Current Investments	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Investment [Text Block]	7. Current and Non-Current Investments At December 31, 2015, the Company held no investments. At December 31, 2014, current and non-current investments consisted of the following securities: December 31, 2014 (In thousands) Cost Unrealized Unrealized Fair Value Current: U.S. government agencies $ 4,203 $ 1 $ - $ 4,204 Certificates of deposit 2,500 - - 2,500 Corporate bonds 4,575 - (3 ) 4,572 U.S. commercial paper 11,109 8 - 11,117 Total $ 22,387 $ 9 $ (3 ) $ 22,393 Non-current: U.S. government agencies $ 8,047 $ - $ (15 ) $ 8,032 Certificates of deposit 5,000 5,000 Corporate bonds 509 - (1 ) 508 Total $ 13,556 $ - $ (16 ) $ 13,540

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Fair Value, Measurement Inputs, Disclosure [Text Block]	8. Fair Value Measurements The Company performs fair value measurements in accordance with the FASB’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value: Level 1 Level 2 Level 3 The carrying values of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, collaboration obligation and other accrued liabilities, approximate their fair values due to their short maturities. The estimated fair value of long term debt as disclosed in note 17 and 18 was based on similar types of borrowings. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. There were no fair value adjustments other than the assets and liabilities acquired under the R-Tech acquisition (see note 5) in the years ended December 31, 2015 and 2014 for nonfinancial assets or liabilities required to be measured at fair value on a non-recurring basis. The Company’s financial instruments measured at fair value on a recurring basis, which are subject to the fair value disclosure requirements, are as follows: There were no transfers between levels during the years ended December 31, 2015 and 2014.

Note 9 - Inventories

Note 9 - Inventories	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Inventory Disclosure [Text Block]	9. Inventories Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. In connection with the acquisition of R-Tech, all inventory held by R-Tech was stepped-up in value to $37.6 million as of the acquisition date. As of December 31, 2015, the remaining balance of inventory step-up was $14.3 million. As of December 31, 2014, the company had no inventory. Inventories consisted of the following as of December 31, 2015: December 31, (In thousands) 2015 Raw materials $ 5,554 Work in process 26,926 Finished goods 641 Total $ 33,121

Note 10 - Property and Equipmen

Note 10 - Property and Equipment	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	10. Property and Equipment Property and equipment consist of the following at December 31, 2015 and 2014: December 31, (In thousands) 2015 2014 Computer and office machines $ 2,647 $ 2,622 Furniture and fixtures 1,023 473 Leasehold improvements 3,066 1,415 Buildings 1,022 - Machinery and equipment 2,074 - Construction in progress 140 - Total cost 9,972 4,510 Less: accumulated depreciation (3,579 ) (3,747 ) Total $ 6,393 $ 763 Depreciation expense for the years ended December 31, 2015, 2014 and 2013 was approximately $637,000, $422,000 and $512,000, respectively. Leasehold improvements as of December 31, 2015 are tenant improvements to the Company’s offices in Rockville, Maryland and Kobe, Japan. Leasehold improvements as of December 31, 2014 are tenant improvements to the Company’s former headquarters in Bethesda, Maryland.

Note 11 - Intangible Assets, In

Note 11 - Intangible Assets, In-process Research and Development and Goodwill	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	11. Intangible Assets, In-Process Research and Development and Goodwill Intangible assets by major class as of December 31, 2015 and 2014 are as follows: December 31, 2015 December 31, 2014 (In thousands) Weighted Carrying Weighted Carrying Amortized intangible assets Patent and license rights 72 $ 10,513 84 $ 10,513 Manufacturing know how 76 134,600 - Accumulated amortization (8,463 ) (4,711 ) Impairment losses (5,651 ) (5,651 ) Foreign currency translation adjustments (684 ) - Total amortized intangible assets $ 130,315 $ 151 Unamortized intangible assets In-process research and development $ 6,171 $ - Goodwill 60,937 - Total unamortized intangible assets $ 67,108 $ - Total intangible assets $ 197,423 $ 151 The changes in intangible assets for the years ended December 31, 2015 and 2014 are as follows: (In thousands) Intangibles Goodwill In-process Balance at December 31, 2013 $ 6,438 $ - $ - Amortization (636 ) - - Impairment losses (5,651 ) - - Balance at December 31, 2014 $ 151 $ - $ - Additions 134,600 61,228 6,200 Amortization (3,752 ) - - Foreign currency translation adjustment (684 ) (291 ) (29 ) Balance at December 31, 2015 $ 130,315 $ 60,937 $ 6,171 Amortization expense on intangible assets totaled approximately $3.7 million, $636,000 and $1.0 million, respectively for the years ended December 31, 2015, 2014 and 2013. There was no impairment charge recorded during the twelve months ended December 31, 2015. The changes in the carrying value of goodwill during the year ended December 31, 2015 resulted from the acquisition and foreign currency translation. In 2014, the Company ceased direct commercialization activities for RESCULA in the United States for its approved FDA indication. Accordingly, the Company recorded an impairment charge of $5.6 million in 2014, which was the full amount of the remaining balances of the unamortized intangibles related to its two RESCULA license agreements. Both license agreements were for the development and commercialization of RESCULA for its approved indication, and for any new indications for unoprostone isopropyl. The estimated fair values of acquired in-process research and development projects which have not reached technological feasibility at the date of acquisition are capitalized and subsequently tested for impairment through completion of the development process, at which point the capitalized amounts are amortized over their estimated useful life. If a project is abandoned rather than completed, all capitalized amounts are written-off immediately. During 2015 and 2014, no development projects were completed and no in-process research and development costs were reclassified into developed technology. As the underlying in-process research and development are in the early stage of development, the Company does not expect to amortize any in-process research and development in 2016. Amortization of intangibles for the next five years is expected to be as follows: (In thousands) Amortization Years ended December 31, 2016 $ 22,689 2017 22,689 2018 22,689 2019 22,689 2020 22,689

Note 12 - Accrued Expenses

Note 12 - Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	12. Accrued Expenses Accrued expenses consist of the following at December 31, 2015 and 2014: December 31, (In thousands) 2015 2014 Research and development costs $ 3,843 $ 3,537 Employee compensation 4,860 3,459 Restructuring 851 - Selling and marketing costs 1 163 Legal service fees 428 612 Other accrued expenses 903 696 Total $ 10,886 $ 8,467

Note 13 - Collaboration Obligat

Note 13 - Collaboration Obligation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	13. Collaboration Obligation Under the Global Takeda Agreement (see note 19), the Company received an upfront payment from Takeda of $14.0 million in 2014, of which the Company is obligated to reimburse Takeda for the first $6.0 million in developmental expenses incurred by Takeda. At December 31, 2015 and 2014, the collaboration obligation was $5.6 million and $6.0 million, respectively.

Note 14 - Other Current Liabili

Note 14 - Other Current Liabilities	12 Months Ended
	Dec. 31, 2015
Other Current Liabilities [Member]
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	14. Other Current Liabilities Other current liabilities consist of the following at December 31, 2015 and 2014: December 31, (In thousands) 2015 2014 Indirect taxes payable 5,963 3,075 Squeeze out liability for non-tendering R-Tech shareholders 7,668 - Other current liabilities 508 543 Total $ 14,139 $ 3,618
Other Liabilities Disclosure [Text Block]	15. Other Liabilities Other liabilities consist of the following at December 31, 2015 and 2014: December 31, (In thousands) 2015 2014 Deferred grants $ 9,604 $ - Unrecognized tax benefits 3,061 - Deferred leasehold incentive 1,715 380 Defined benefit obligation 949 977 Other liabilities 414 579 Total $ 15,743 $ 1,936 Deferred grants consist of a $9.3 million interest-free grant from the Japan Science and Technology Agency for use in developing unoprostone-related medicine for pigmentary degeneration of the retina, and a $300,000 government grant from Montgomery County, Maryland related to the move of the Company’s headquarters. Both grants may have to be repaid if certain conditions are not met. Defined benefit obligation relates to defined benefit pension plans for employees in the Company’s subsidiary in Switzerland (Swiss Plan). The Swiss Plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 1.75% in 2015 and 1.75% in 2014. Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee’s contribution. Minimum employee contributions are based on the respective employee’s age, salary, and gender. As of December 31, 2015, the Swiss Plan had an unfunded net pension obligation of approximately $949,000, plan assets of approximately $1.6 million and projected benefit obligation of approximately $2.5 million. As of December 31, 2014, the Swiss Plan had an unfunded net pension obligation of approximately $977,000, plan assets of approximately $1.8 million and projected benefit obligation of approximately $2.8 million. The entire liability is listed as non-current because plan assets are more than enough to pay expected benefit payments over the next year. The Company recognized pension expense of $226,000 and $221,000 for the years ended December 31, 2015 and 2014, respectively, related to the Swiss Plan. While the Swiss Plan originated in 2011, the Company only accounted for the Swiss Plan in accordance with ASC 715-30 Defined Benefit Plans - Pensions The following tables provide reconciliations of the changes in the Swiss Plan’s projected benefit obligations and assets, and the assumptions used at December 31, 2015 and 2014. Reconciliation of Projected Benefit Obligation December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation at beginning of year $ 2,760 $ 1,708 Service cost 164 191 Interest cost 28 43 Plan participants’ contributions 90 165 Plan amendments (39 ) - Actuarial loss (gain) - 653 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Projected benefit obligation at end of year $ 2,513 $ 2,769 Reconciliation of Fair Value of Plan Assets December 31, 2015 December 31, 2014 (in thousands) Fair value of plan assets at beginning of year $ 1,787 $ 1,342 Actual return on plan assets 42 42 Employer contribution 136 234 Plan participants’ contributions 90 165 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Fair value of plan assets at end of year $ 1,565 $ 1,792 Funded status at end of year $ (948 ) $ (977 ) Reconciliation of amounts recognized in Consolidated Statements of Operations and Comprehensive Income Year ended Year ended (in thousands) Net loss $ (862 ) $ (978 ) Total amount recognized in accumulated other comprehensive income $ (862 ) $ (978 ) Accumulated contributions in excess of net periodic benefit cost (87 ) 1 Funded status at end of year $ (949 ) $ (977 ) Net periodic pension cost included the following components Year ended Year ended (in thousands) Service cost $ 164 $ 191 Interest cost 28 43 Expected return on assets (39 ) (30 ) Amortization of unrecognized net loss 73 17 Net periodic pension cost $ 226 $ 221 Changes in plan assets and benefit obligations recognized in other comprehensive income Year ended Year ended (in thousands) New prior service cost $ (39 ) $ - Net loss arising during year (2 ) 641 Amortization or settlement of net loss (73 ) (17 ) Total recognized in other comprehensive income $ (114 ) $ 624 Total loss recognized in net periodic cost and other comprehensive income $ 111 $ 845 Estimated amounts to be amortized from accumulated other comprehensive income over the next year December 31, 2015 December 31, 2014 (in thousands) Net loss $ 76 $ 73 Additional year-end information for plans with projected benefit obligations in excess of plan assets December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation $ 2,514 $ 2,769 Accumulated benefit obligation 2,233 2,469 Fair value of plan assets 1,566 1,792 Weighted average allocation of plan assets December 31, 2015 December 31, 2014 Debt Securities 78 % 79 % Real Estate 12 % 12 % Other Investments 8 % 6 % Cash 2 % 3 % Total 100 % 100 % Weighted average assumptions used to determine net periodic pension cost Year ended Year ended Discount or settlement rates 1.0 % 2.5 % Expected long-term rates of return on assets 2.1 % 2.1 % Rates of increase in compensation levels 1.5 % 1.5 % Weighted average assumptions used to determine future benefit obligations December 31, 2015 December 31, 2014 Discount rate 0.9 % 1.0 % Rates of increase in compensation levels 1.5 % 1.5 % Expected future cash flows (in thousands) Employee Contributions 2016 $ 155 $ 151 Benefit Payments 2016 7 145 2017 12 10 2018 17 14 2019 23 18 2020 28 23 2021-2025 634 494

Note 15 - Other Liabilities

Note 15 - Other Liabilities	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	15. Other Liabilities Other liabilities consist of the following at December 31, 2015 and 2014: December 31, (In thousands) 2015 2014 Deferred grants $ 9,604 $ - Unrecognized tax benefits 3,061 - Deferred leasehold incentive 1,715 380 Defined benefit obligation 949 977 Other liabilities 414 579 Total $ 15,743 $ 1,936 Deferred grants consist of a $9.3 million interest-free grant from the Japan Science and Technology Agency for use in developing unoprostone-related medicine for pigmentary degeneration of the retina, and a $300,000 government grant from Montgomery County, Maryland related to the move of the Company’s headquarters. Both grants may have to be repaid if certain conditions are not met. Defined benefit obligation relates to defined benefit pension plans for employees in the Company’s subsidiary in Switzerland (Swiss Plan). The Swiss Plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 1.75% in 2015 and 1.75% in 2014. Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee’s contribution. Minimum employee contributions are based on the respective employee’s age, salary, and gender. As of December 31, 2015, the Swiss Plan had an unfunded net pension obligation of approximately $949,000, plan assets of approximately $1.6 million and projected benefit obligation of approximately $2.5 million. As of December 31, 2014, the Swiss Plan had an unfunded net pension obligation of approximately $977,000, plan assets of approximately $1.8 million and projected benefit obligation of approximately $2.8 million. The entire liability is listed as non-current because plan assets are more than enough to pay expected benefit payments over the next year. The Company recognized pension expense of $226,000 and $221,000 for the years ended December 31, 2015 and 2014, respectively, related to the Swiss Plan. While the Swiss Plan originated in 2011, the Company only accounted for the Swiss Plan in accordance with ASC 715-30 Defined Benefit Plans - Pensions The following tables provide reconciliations of the changes in the Swiss Plan’s projected benefit obligations and assets, and the assumptions used at December 31, 2015 and 2014. Reconciliation of Projected Benefit Obligation December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation at beginning of year $ 2,760 $ 1,708 Service cost 164 191 Interest cost 28 43 Plan participants’ contributions 90 165 Plan amendments (39 ) - Actuarial loss (gain) - 653 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Projected benefit obligation at end of year $ 2,513 $ 2,769 Reconciliation of Fair Value of Plan Assets December 31, 2015 December 31, 2014 (in thousands) Fair value of plan assets at beginning of year $ 1,787 $ 1,342 Actual return on plan assets 42 42 Employer contribution 136 234 Plan participants’ contributions 90 165 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Fair value of plan assets at end of year $ 1,565 $ 1,792 Funded status at end of year $ (948 ) $ (977 ) Reconciliation of amounts recognized in Consolidated Statements of Operations and Comprehensive Income Year ended Year ended (in thousands) Net loss $ (862 ) $ (978 ) Total amount recognized in accumulated other comprehensive income $ (862 ) $ (978 ) Accumulated contributions in excess of net periodic benefit cost (87 ) 1 Funded status at end of year $ (949 ) $ (977 ) Net periodic pension cost included the following components Year ended Year ended (in thousands) Service cost $ 164 $ 191 Interest cost 28 43 Expected return on assets (39 ) (30 ) Amortization of unrecognized net loss 73 17 Net periodic pension cost $ 226 $ 221 Changes in plan assets and benefit obligations recognized in other comprehensive income Year ended Year ended (in thousands) New prior service cost $ (39 ) $ - Net loss arising during year (2 ) 641 Amortization or settlement of net loss (73 ) (17 ) Total recognized in other comprehensive income $ (114 ) $ 624 Total loss recognized in net periodic cost and other comprehensive income $ 111 $ 845 Estimated amounts to be amortized from accumulated other comprehensive income over the next year December 31, 2015 December 31, 2014 (in thousands) Net loss $ 76 $ 73 Additional year-end information for plans with projected benefit obligations in excess of plan assets December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation $ 2,514 $ 2,769 Accumulated benefit obligation 2,233 2,469 Fair value of plan assets 1,566 1,792 Weighted average allocation of plan assets December 31, 2015 December 31, 2014 Debt Securities 78 % 79 % Real Estate 12 % 12 % Other Investments 8 % 6 % Cash 2 % 3 % Total 100 % 100 % Weighted average assumptions used to determine net periodic pension cost Year ended Year ended Discount or settlement rates 1.0 % 2.5 % Expected long-term rates of return on assets 2.1 % 2.1 % Rates of increase in compensation levels 1.5 % 1.5 % Weighted average assumptions used to determine future benefit obligations December 31, 2015 December 31, 2014 Discount rate 0.9 % 1.0 % Rates of increase in compensation levels 1.5 % 1.5 % Expected future cash flows (in thousands) Employee Contributions 2016 $ 155 $ 151 Benefit Payments 2016 7 145 2017 12 10 2018 17 14 2019 23 18 2020 28 23 2021-2025 634 494

Note 16 - Commitments and Conti

Note 16 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and Contingencies Operating Leases The Company leases office space in the U.S., Switzerland and Japan. In Japan the Company also leases a research and development facility and a manufacturing facility. At December 31, 2015, total future minimum non-cancelable lease payments under operating leases are as follows: (In thousands of U.S. dollars) December 31, 2016 $ 1,781 2017 941 2018 1,233 2019 1,020 2020 966 Total minimum lease payments $ 5,941 Rent expense for all operating leases was $1.8 million, $1.4 million and $1.5 million for the years ended December 31, 2015, 2014 and 2013, respectively. Research and Development Costs The Company routinely enters into agreements with third-party CROs to oversee clinical research and development studies provided on an outsourced basis and assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. The maximum contingent liability under the Numab Agreement (see note 17) in the event that Numab defaults under its loan with Zurcher Kantonalbank is $2.2 million. As of December 31, 2015, due to the pay down of the loan with Zurcher Kantonalbank, the potential amount of payments in the event of Numab’s default is $1.5 million.

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. Related Party Transactions R-Tech Ueno, Ltd. Before the R-Tech acquisition, R-Tech had been considered a related party. Drs. Ryuji Ueno and Sachiko Kuno are married to each other and prior to 2015, directly or indirectly, owned the majority of the stock of R-Tech. Drs. Ueno and Kuno are also controlling stockholders of S&R Technology Holding, LLC (S&R), which in turn owned approximately 47% of the Company’s common stock and 44% of R-Tech’s common stock. Dr. Ueno was the Company’s Chief Executive Officer and Chairman of the Company’s Board of Directors through March 3, 2014 and was our Chief Scientific Officer through March 18, 2014. Prior to the R-Tech acquisition on October 20, 2015 (see note 5), the Company did not own manufacturing facilities. Instead, the Company contracted with R-Tech as the sole manufacturer of the Company’s products to produce AMITIZA and RESCULA. The Company had entered into multiple exclusive supply arrangements with R-Tech and had granted to R-Tech the exclusive right to manufacture and supply AMITIZA and other products and compounds to the Company to meet its commercial and clinical requirements. Since 2003, the Company has received upfront, development and milestone payments under these agreements totaling $9.0 million through October 20, 2015. The Company recorded the following expenses under all of its agreements with R-Tech for the period January 1, 2015 through October 20, 2015, and for the years ended December 31, 2014 and 2013: January 1 Year Ended December 31, (In thousands) 2015 2014 2013 Clinical supplies $ 155 $ 396 $ 827 Other research and development services 347 171 194 Commercial supplies 21,415 15,776 14,902 $ 21,917 $ 16,343 $ 15,923 Deferred revenues under the Company’s agreements with R-Tech consist of the following at December 31, 2015 and 2014. Year Ended December 31, (In thousands) 2015 2014 Deferred revenue, current $ - $ 453 Deferred revenue, non-current - 4,141 $ - $ 4,594 The decrease in deferred revenue from $4.6 million as of December 31, 2014 to zero as of December 31, 2015 was primarily due to the settlement of a pre-existing relationship upon acquiring R-Tech on October 20, 2015. Numab AG In September 2011, the Company entered into the Numab Agreement with Numab. Under the terms of the Numab Agreement, which extends through September, 2016, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.2 million as of December 31, 2015. As of December 31, 2015, collateral of CHF 2.2 million had been deposited by the Company and Numab has utilized CHF 1.5 million of its loan facility, or approximately $1.5 million. At December 31, 2015 and 2014, the Company has a recorded guarantee liability of $202,000 and $1.0 million, respectively, in collateral callable to meet a potential loan default by Numab. Subordinated Unsecured Promissory Notes In connection with the SAG acquisition in 2010, the Company issued a subordinated unsecured promissory note (Notes) to the Ueno Trust and Kuno Trust, former shareholders of SAG. The Ueno Trust and Kuno Trust are considered related parties. Each of the Notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the Notes is the sum of the London Interbank Offered Rate, or LIBOR, plus 4.0%, and is reset on December 1st and June 1st each year. The interest rate beginning December 1, 2015 is 4.7%. On February 1, 2016, these Notes were paid in full.

Note 18 - Notes Payable

Note 18 - Notes Payable	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	18. Notes Payable On October 16, 2015, the Company entered into a Credit Agreement (Credit Facility) with Jefferies Financing LLC. The Credit Facility provides for term loans in the aggregate principal amount of $250.0 million (Term Loans) and allows for the incurrence of incremental loans in an amount up to $25.0 million on the terms and subject to the conditions set forth in the Credit Facility. The Term Loans bear interest, at the Company’s option, at the Adjusted Eurodollar Rate plus 7.25% or the Adjustable Base Rate plus 6.25%. The Adjusted Eurodollar Rate is subject to a 1.00% floor and the Adjusted Base Rate is subject to a 2.00% floor. The Company must repay the Term Loans in installments of $6.25 million on the last business day of each quarter, starting in March 2016 and ending in September 2021, with the balance due in a final installment on October 16, 2021. The Company is prohibited from paying dividends under the terms of the agreement. The Company’s payment obligations under the Credit Facility are secured by a lien on substantially all of the Company’s tangible and intangible assets, subject to certain limitation and restrictions. The Credit Facility contains certain affirmative, negative, financial and reporting covenants customary for financing of this type. The credit facility requires that the Company maintain at least $25.0 million in a restricted cash collateral account, until at least $35.0 million in aggregate principal amount of initial term loans has been prepaid or repaid. Affirmative covenants in the Credit Facility require that the Company prepay principal of the term loans in an amount equal to certain thresholds of excess cash as defined in the credit facility. The Company has the ability to repay the loans early in increments no less than $1 million, subject to a 2% early payment penalty if paid in year 1 and a 1% early payment penalty if paid in year 2. Thereafter, there is no early payment penalty. In addition, the Company must preserve the existence of the legal entity, maintain the property and insurance and comply with all laws and contractual obligations. The credit facility also contains certain financial covenants, tested quarterly and in connection with any triggering event under the credit facility that include the maintenance of a total leverage ratio as of the last day of any fiscal quarter of 3.25 to 1.00 for the period ending December 31, 2015 through December 31, 2016. Thereafter, it decreases to 2.40 to 1.00 at December 31, 2017, 1.60 to 1.00 at December 31, 2018 and .80 to 1.00 at December 31, 2019. Negative covenants in the credit facility limit the Company’s ability to, among other things: incur additional indebtedness or swap obligations, without triggering a repayment event, incur or permit any lien on any property or asset, dispose of material assets in excess of $2 million, make investments including loans in excess of $15 million or merge or divest a line of business or subsidiary. Upon the occurrence and continuance of an event of default under the credit facility, the commitments of the lenders to make loans under the credit facility may be terminated and the Company’s payment obligation under the credit facility may be accelerated. The event of default under the credit facility include, among others, subject in some cases to specified cure periods: payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of a final judgement in excess of a threshold amount; a material ERISA event; change of control; an impairment of collateral; and invalidity of loan documents relating to the credit facility. The Company was in compliance with all the covenants under the credit facility at December 31, 2015. Company maturities of notes payable over the next five years are as follows: (In thousands) Amount Years ended December 31, 2016 $ 42,582 2017 25,000 2018 25,000 2019 25,000 2020 25,000

Note 19 - Collaboration and Lic

Note 19 - Collaboration and License Agreements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Collaborative and License Arrangement Disclosure [Text Block]	19. Collaboration and License Agreements North America Takeda Agreement In October 2004, the Company entered into an agreement with Takeda to supply, develop and commercialize AMITIZA for gastrointestinal indications in the U.S. and Canada. The original agreement was amended on February 1, 2006 through a supplemental agreement, and in October 2014 the Company and Takeda and certain Takeda affiliates executed amendments to the agreement. Collectively, these are referred to as the North America Takeda Agreement. Payments to the Company under these agreements include a non-refundable upfront payment, non-refundable development and commercial milestone payments, reimbursement of certain development and co-promotion costs, and product royalties. The Company has received a total of $160.0 million in upfront and development milestone payments through December 31, 2015 under the North America Takeda Agreement, including a $10.0 million development milestone received in the second quarter of 2013 for the first commercial sale of AMITIZA for OIC. Subject to development and acceptance of future indications, the Company is potentially entitled to receive additional development milestone and commercial milestone payments under the North America Takeda Agreement, although there can be no assurance that the Company will receive any such payments. The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the year ended December 31, 2015: Cash Revenue Recognized for the Year Ended December 31, Accounts Amount (In thousands) 2015 Through 2013 2014 2015 2015 (1) 2015 Product royalty revenue $ 405,410 $ 291,427 $ 62,775 $ 74,000 $ 22,792 $ - Product sales revenue $ 996 $ - $ - $ 10,311 $ 9,315 $ - Research and development revenue: Up-front payment - remainder $ 17,624 $ 17,624 $ - $ - $ - $ - Development milestones 140,000 140,000 - - - - Reimbursement of research and development expenses 131,432 116,805 7,221 10,164 2,758 - Total $ 289,056 $ 274,429 $ 7,221 $ 10,164 $ 2,758 $ - Collaboration revenue: Supply agreements - Manufacturing $ 2,337 $ - $ - $ 2,337 $ - $ - Up-front payment associated with the Company's obligation to participate in joint committees $ 2,376 $ 1,346 $ 147 $ 147 $ - $ 736 Total $ 4,713 $ 1,346 $ 147 $ 2,484 $ - $ 736 Co-promotion revenue $ 32,813 $ 29,453 $ 3,360 $ - $ - $ - (1) Includes billed and unbilled accounts receivable. Upon execution of the North America Takeda Agreement, the Company was required to complete several deliverables, which Takeda was responsible to fund. The following are the required deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company relating to research and development revenue: · Upon receipt of the $20.0 million upfront payment, the Company deferred approximately $2.4 million to be recognized using the time-based model over the performance period of the participation in various joint committee meetings. The Company expects its participation on all committees to continue throughout the term of the North America Takeda Agreement. During each of the years ended December 31, 2015, 2014 and 2013, the Company recognized approximately $147,000 of this deferred amount as collaboration revenue on the Consolidated Statements of Operations and Comprehensive Income. · The Company granted Takeda an exclusive license of lubiprostone to co-develop, commercialize, and sell products for gastroenterology indications in the U.S. and Canada. The Company has recorded product royalty revenue of approximately $74.0 million, $62.8 million; and $52.1 million for the years ended December 31, 2015, 2014 and 2013, respectively. This revenue is recorded as product royalty revenue in the Consolidated Statements of Operations and Comprehensive Income. · The Company has provided development work necessary for an NDA submission to the FDA for the treatment of CIC and IBS-C indications. Takeda funded the initial $30.0 million of development costs, the Company was obligated to fund the first $20.0 million in excess of the initial $30.0 million funded by Takeda and the two parties are to equally share any required development costs in excess of $50.0 million. Although there was no defined performance period for this development work, the period to perform the work would not exceed the term of the North America Takeda Agreement. In January 2006, the Company received approval for its NDA for AMITIZA to treat CIC and completed and submitted the supplemental NDA for IBS-C to the FDA in June 2007. · In conjunction with the R-Tech acquisition in October 2015, the Company now recognizes product sales through the North America Takeda Agreement. The Company has recorded product sales revenue of approximately $10.3 million for the year ended December 31, 2015. The Company initially deferred the residual amount of the $20.0 million upfront payment totaling approximately $17.6 million, development milestone payments received totaling $50.0 million, and reimbursement of the initial $30.0 million of research and development costs for the development of AMITIZA for CIC and IBS-C indications. These deferred amounts were applied towards the unit of accounting that combines the participation in the joint development committee and the development of CIC and IBS-C and was recognized over the performance period of developing the CIC and IBS-C NDA submissions. The Company completed the development of the CIC and IBS-C in June 2007 and filed a sNDA for IBS-C. This was the culmination of the performance period. In June 2007, the Company also recognized as revenue, in full, $30.0 million from Takeda upon the filing of the sNDA for AMITIZA to treat IBS-C. The Company received a $50.0 million development milestone from Takeda as a result of the FDA’s approval on April 29, 2008 of the sNDA for IBS-C in women aged 18 years and older and recognized the payment as research and development revenue during the year ended December 31, 2008. During 2006, the joint commercialization committee granted approval for the Company and Takeda to begin three new studies. The following are the three additional deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company, when the three studies were agreed upon: · The Company is obligated to perform studies in connection with changes to labeling for CIC. Takeda is obligated to fund 70% of the labeling studies and the Company is obligated to fund the remaining 30%. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement. · The Company is obligated to perform studies for the development of an additional indication for OIC. Takeda is obligated to fund all development work up to a maximum aggregate of $50.0 million for each additional indication and $20.0 million for each new formulation. If development costs exceed these amounts, Takeda and the Company shall equally share such excess costs. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement. The Company decided to conduct one additional phase 3 efficacy studies in order to submit a sNDA for the OBD indication. In February 2012, the Company announced that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of OBD in patients with chronic, non-cancer pain, excluding those taking methadone. · The Company is obligated to perform all development work necessary for phase 4 studies, for which Takeda is obligated to fund all development work. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement. The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. As a result of the Company and Takeda agreeing to perform and fund these studies simultaneously, the Company determined that there is no objective and reliable evidence to determine the fair value for each of the studies. Accordingly, the Company has combined these three required deliverables as a single unit of accounting. All cash payments from Takeda related to these three deliverables are deferred upon receipt and recognized over the estimated performance period to complete the three studies using the time-based model. In 2011, the Joint Commercialization Committee (JCC) granted approval to begin studies for a liquid formulation. In addition, in 2012, the JCC granted approval for studies for a pediatric dosage. These additional deliverables are considered separate units of accounting and the Company recognizes revenue from Takeda reimbursements for these deliverables when earned. Co-promotion costs after May 31, 2011 were reimbursed under the Takeda Agreement. The Company has recognized approximately zero, $3.4 million and $61,000 of revenues for the years ended December 31, 2015, 2014 and 2013, respectively, which is recorded as co-promotion revenue in the Consolidated Statements of Operations and Comprehensive Income. The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. The Company determined that its sales force and miscellaneous marketing activities are treated as separate units of accounting. The Company is recognizing the cost reimbursements received for these deliverables as co-promotion revenues when services are performed and the reimbursement payments are due under the Supplemental Takeda Agreement. Global Takeda Agreement In October 2014, the Company and Takeda entered into the Global Takeda Agreement to develop and commercialize AMITIZA. The territories excluded from the Global Takeda Agreement are Canada, the U.S., Japan and the People’s Republic of China. Canada and the U.S. are covered by the North America Takeda Agreement, and Japan is covered by the Japan Mylan Agreement. Switzerland and the U.K. have already received regulatory approval for AMITIZA to be marketed and sold. All other territories covered under the Global Takeda Agreement will need to have regulatory approval before AMITIZA can be sold. Under the terms of the Global Takeda Agreement, the Company supplies Takeda with AMITIZA at a negotiated supply price. The Company also received a nonrefundable upfront payment of $14.0 million from Takeda for exclusive rights to develop and commercialize AMITIZA in the global markets covered by the Global Takeda Agreement. In addition, the Company is also eligible for up to $35.0 million in additional commercial milestone payments contingent on the achievement of certain net sales revenue targets. Takeda is responsible for all development activities and costs, except that the Company will assume responsibility for the first $6.0 million of those development expenses incurred by Takeda. The Global Takeda Agreement is considered a multiple-element arrangement for accounting purposes. The Company identified the rights to use the Company’s license to develop and commercialize AMITIZA and the sale of AMITIZA product at a negotiated price as the deliverables. During the fourth quarter of 2014, the Company received a $14.0 million milestone payment and allocated $8.0 million to the right to use the license and $6.0 million to a collaboration obligation to reimburse Takeda for the first $6.0 million in developmental expenses incurred. There were no product sales to Takeda under the Global Takeda Agreement during 2014 and 2015. Japan Mylan Agreement In February 2015, Abbott and Mylan closed Mylan’s purchase of Abbott’s non-U.S. developed markets specialty and branded generics business, which included the Company’s February 2009 Japan Mylan Agreement to develop and commercialize lubiprostone for the treatment of CIC in Japan. The Company did not experience any significant changes in the commercialization of AMITIZA in Japan as a result of the transfer of the Japan Mylan Agreement from Abbott to Mylan. The Japan Mylan Agreement grants Mylan the right of exclusive negotiation to any additional indications for which lubiprostone is developed in Japan under all relevant patents, know-how and trademarks. Under the terms of the Japan Mylan Agreement, payments to the Company include sales of product at a negotiated sales price, a non-refundable upfront payment and non-refundable development and commercial milestone payments based on achieving specified development, regulatory and sales goals. The collaboration efforts under the agreement are governed by two committees consisting of an equal number of representatives from both parties. The joint commercialization and steering committee oversees commercialization-related activities and resolves any conflicts arising from a joint development committee, which oversees the development-related activities in Japan. The Company is required to fund and complete all the development work including additional clinical studies required to obtain regulatory approval for the treatment of CIC in Japan. The Company completed all development activities in the fourth quarter of 2012. The Company owns all the rights covered under the regulatory filings. Mylan is required to fund and undertake all commercialization efforts including pre-launch and post-launch marketing, promotion and distribution. Mylan is required to maintain the number of sales staff and the estimated level of annual net sales based on the commercialization plan to be developed and approved by the joint commercialization and steering committee described above. The Company has recorded product sales revenue under the Japan Mylan Agreement of approximately $53.9 million and $32.1 million for the years ended December 31, 2015 and 2014, which includes a $5.0 million and a $2.5 million net sales milestone, respectively. As of December 31, 2015, the Company has received a total of $37.5 million in up-front and development milestone payments under the Japan Mylan Agreement. Under the Japan Mylan Agreement, the Company could receive additional milestone payments based on achieving other specified development and commercialization goals although there can be no assurance that the Company will receive any such payments. The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Mylan Agreement for the year ended December 31, 2015: Cash Revenue Recognized for the Year Ended Accounts Foreign Amount (In thousands) 2015 Through 2013 2014 2015 2015 Effects 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 846 $ 241 $ 39 $ 34 $ - $ 116 $ 416 Research and development revenue Up-front payment - remainder $ 9,154 $ 9,302 $ - $ - $ - $ (148 ) $ - Development milestone payment 27,500 27,755 - 5,000 5,000 (255 ) - Total $ 36,654 $ 37,057 $ - $ 5,000 $ 5,000 $ (403 ) $ - Product sales revenue $ 96,937 $ 20,830 $ 32,088 $ 48,908 $ 4,958 $ 69 $ - China Gloria Agreement In May 2015, the Company entered into an exclusive license, development, commercialization and supply agreement (China Gloria Agreement), for AMITIZA in the People’s Republic of China. The China Gloria Agreement is effective until the thirteenth anniversary of the effective date and will automatically renew for successive three year periods unless terminated upon one year’s prior written notice by one of the parties. Under the terms of the China Gloria Agreement: · The Company received an upfront payment of $1.0 million from Gloria during May 2015 and an upfront payment of $500,000 in June 2015 after the CFDA accepted the IND application for a pivotal trial of AMITIZA in patients with CIC. · The Company is eligible to receive an additional payment in the amount of $1.5 million upon the occurrence of a specified regulatory or commercial milestone event. · Gloria is responsible for all development activities and costs, as well as commercialization and regulatory activities, for AMITIZA in the People’s Republic of China. · The Company will be the exclusive supplier of AMITIZA to Gloria at an agreed upon supply price. RESCULA Agreement Japan Santen Agreement In March 2012, R-Tech entered into an exclusive transaction agreement (Japan Santen Agreement) with Santen Pharmaceutical Co. Ltd (Santen) to commercialize RESCULA in Japan. The initial term of the Japan Santen Agreement ends on March 31, 2016; thereafter, the agreement automatically extends for successive one-year renewal terms unless either party gives the other party an 11-month prior notice. Under the terms of the Japan Santen Agreement: · The Company recognizes revenues from the product sales of RESCULA to Santen at a negotiated price. · During 2015, the Company recognized $1.5 million of RESCULA revenue.

Note 20 - Stockholders' Equity

Note 20 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	20. Stockholders’ Equity Capital Structure The Company has two classes of common stock authorized: class A common stock and class B common stock. In 2012, the company’s majority stockholder and only holder of the Company’s class B common stock converted all of its outstanding shares of class B common stock into shares of the Company’s class A common stock. The Company is not authorized to issue additional shares of class B common stock except in limited circumstances. As a result of the conversion, there is now only a single class of outstanding common stock, class A common stock, which is entitled to one vote per share. Cantor Sales Agreement In January 2013, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (Cantor Sales Agreement), which enables the Company to offer and sell up to an aggregate of $20.0 million of shares of its class A common stock through Cantor Fitzgerald & Co. as the Company’s sales agent. Sales of the Company’s class A common stock under the Cantor Sales Agreement are sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (Securities Act). Cantor Fitzgerald & Co. is entitled to receive a commission of 3.0% of gross sales in connection with the sale of the Company’s class A common stock. During the year ended December 31, 2014, the Company sold an aggregate of 538,521 shares of its class A common stock, and received gross proceeds of approximately $5.5 million, before deducting issuance expenses, pursuant to the Cantor sales Agreement. The Company terminated the Cantor Sales Agreement in November 2015. Treasury Stock In 2008, the Company announced a stock repurchase program under which the Company is authorized to purchase up to $10.0 million of its class A common stock from time to time in open-market transactions. In 2011, the Board authorized the repurchase of up to an aggregate of $2.0 million of the Company’s class A common stock out of the $10.0 million authorized by the Board in 2008. In 2012, the Board authorized the increase of such amount of repurchase to up to an aggregate of $5.0 million. In 2013, the Company repurchased 67,762 shares of its class A common stock under this program at a cost of $336,000. All shares of class A common stock purchased in 2013 were purchased in January, February and March of 2013. On October 20, 2015, as part of the R-Tech acquisition, the Company acquired 2,485,150 shares of the Company’s class A common stock. As part of the R-Tech purchase price allocation, $44.0 million was allocated to these shares based on the October 20, 2015 closing price of $17.68 per share. Employee Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method. The fair value of awards granted is estimated at the date of grant and recognized as expense on a straight-line basis over the requisite service period with the offsetting credit to additional paid-in capital. For awards with performance conditions, the Company recognizes the compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of achieving the performance condition at each reporting date. The assumptions used to estimate the fair value of stock options granted for the years ended December 31, 2015, 2014 and 2013 were as follows: Year Ended December 31, 2015 2014 2013 Expected volatility 54% - 70% 70% - 72% 65% - 75% Risk-free interest rate 1.34% - 1.93% 1.63% - 2.01% 1.23% - 1.40% Expected term (in years) 5.28 - 6.25 5.28 - 6.25 5.50 - 6.25 Expected dividend yield 0% 0% 0% Employee stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 has been reduced for estimated forfeitures as such expense is based upon awards expected to ultimately vest. Estimated forfeiture rates used during the years ended December 31, 2015, 2014 and 2013 ranged from 10.0% to 30.94%. Employee stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2015, 2014 and 2013 was as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Research and development expense $ 2,165 $ 349 $ 293 General and administrative expense 5,053 1,816 1,260 Selling and marketing expense 131 122 191 Total 7,349 2,287 1,744 Stock Option Plans Amended and Restated 2001 Stock Incentive Plan In 2001, the Company adopted the 2001 Stock Incentive Plan (2001 Plan) to provide common stock incentives to certain eligible employees, officers, directors, consultants and advisors of the Company. In 2003, the Board amended the 2001 Plan (Amended 2001 Plan) to allow for a maximum of 8,500,000 shares of class A common stock to be issued under all awards. In August 2005, the Board granted 510,000 stock options to non-employees under the Amended 2001 Plan. These non-employee stock options vested immediately and had a weighted average exercise price per share of $5.85. In 2006, the Board determined no further options would be granted under the Amended 2001 Plan. Non-employee options outstanding and exercisable under the Amended 2001 Plan at December 31, 2015 and 2014 were zero and 255,000, respectively, with a remaining contractual life of zero and .25 years, respectively. During 2015 and 2014, 127,500 and 155,000 options were exercised, respectively, with an aggregate intrinsic value of $1.0 million and $0.3 million, respectively. The Company received $0.7 million and $0.9 million upon the exercise of these options in 2015 and 2014, respectively. A summary of non-employee stock option activity for the year ended December 31, 2015 under the Amended 2001 Plan is presented below: Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 255,000 $ 5.85 Options exercised (127,500 ) 5.85 Options expired (127,500 ) 5.85 Options outstanding, December 31, 2015 - $ - Options exercisable, December 31, 2015 - $ - Options vested and expected to vest, December 31, 2015 - $ - Employee options outstanding and exercisable under the Amended 2001 Plan at December 31, 2015 and 2014 totaled 37,400 and 113,900 respectively, with a remaining contractual life of .34 years and .93 years, respectively. During 2015 and 2014, 76,500 and 6,800 options were exercised, respectively, with an aggregate intrinsic value of $0.6 million and $28,000, respectively. The Company received $0.8 million and $68,000 upon the exercise of these options in 2015 and 2014, respectively. A summary of the employee stock option activity for the year ended December 31, 2015 under the Amended 2001 Plan is presented below: Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 113,900 $ 10.00 Options exercised (76,500 ) 10.00 Options outstanding, December 31, 2015 37,400 10.00 0.34 $ 272,646 Options exercisable, December 31, 2015 37,400 10.00 0.34 $ 272,646 Options vested and expected to vest, December 31, 2015 37,400 10.00 0.34 $ 272,646 2006 Stock Incentive Plan In 2006, the Board approved the 2006 Stock Incentive Plan, which has been amended and restated (as amended and restated, 2006 Plan), and reserved 8,500,000 shares of class A common stock for issuance under the 2006 Plan. Option awards under the 2006 Plan are granted with an exercise price equal to the closing market price of the Company’s stock on the date of grant. The options generally vest over four years and have a ten-year contractual term. At December 31, 2015, there were 2,083,077 shares available for future grants under this plan. The 2006 Plan includes an “evergreen” provision by which the number of shares of the Company’s class A common stock available for issuance increases automatically on the first day of each calendar year by 5.0% of the aggregate number of shares of the Company’s class A and B common stock outstanding on such date, or such lesser number as the Board may determine. The 2006 Plan also provides that the number of shares of class A common stock included in each annual increase will be 500,000, or such lesser number as the Board may determine. The Board determined that the amount of the increase in the shares available for issuance under the 2006 Plan as of January 1, 2015 and 2014 pursuant to the “evergreen” provision was zero. A summary of the employee stock option activity for the year ended December 31, 2015 under the 2006 Plan is presented below: Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 4,021,491 $ 6.93 Options granted 1,321,634 15.18 Options exercised (693,077 ) 5.93 Options forfeited (205,516 ) 10.45 Options expired (3,924 ) 4.09 Options outstanding, December 31, 2015 4,440,608 9.37 8.23 $ 35,461,431 Options exercisable, December 31, 2015 1,763,116 7.07 6.89 $ 18,019,310 Options vested and expected to vest, December 31, 2015 3,581,991 8.99 8.02 $ 29,896,200 During 2015 the 200,000 market-based stock options held by the Company’s Chief Executive Officer attained the award’s performance goal and began vesting ratably through 2018. This event had an insignificant impact on the stock-based compensation expense in 2015. Additionally in 2015 450,000 time-based stock options with accelerated vesting conditions held by certain eligible employees fully vested upon achieving the award’s goals. Stock-based compensation expense for the year ended December 31, 2015 increased approximately $1.0 million as a result of this event. T stock options granted in 2015 totaled 1,321,634. These options vest in equal annual installments over four years from date of grant, and expire ten years from date of grant. The weighted average grant date fair value of options granted during the years ended December 31, 2015, 2014 and 2013 were $15.18, $7.68 and $7.36, respectively. As of December 31, 2015, approximately $9.8 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 2.8 years. When an option is exercised, the Company issues a new share of class A common stock. During 2015 and 2014, 693,077 options and 618,377 options were exercised, respectively, with an aggregate intrinsic value of $8.6 million and $3.0 million, respectively. The Company received $4.1 million and $2.8 million upon the exercise of these options in 2015 and 2014, respectively. Employee Stock Purchase Plan In 2006, the Board approved a 2006 Employee Stock Purchase Plan (ESPP) and reserved 4,250,000 shares of class A common stock for issuance under the ESPP. The ESPP is non-compensatory and is intended to qualify as an Employee Stock Purchase Plan as defined in Section 423 of the Internal Revenue Code of 1986, as amended. Under the ESPP, eligible employees may purchase common stock through payroll deductions of up to 10.0% of compensation during the plan period. On January 19, 2015, the Compensation Committee of the Board approved the change in the purchase price to 85.0% of market price at the end of each plan period, which is generally three months. A total of 9,085 shares, 5,853 shares, and 3,625 shares of common stock were purchased by employees under the ESPP during the years ended December 31, 2015, 2014 and 2013, respectively. The Company received approximately $128,000, $35,000, and $24,000 from the purchase of shares under the ESPP for the years ended December 31, 2015, 2014 and 2013, respectively. Tax Benefits As of December 31, 2015, the balance of the Company's additional paid-in capital pool related to tax windfall benefits from the stock option exercises was $2.5 million. The Company applies a with-and-without approach in determining its intra-period allocation of tax expense or benefit attributable to stock based compensation deductions. Since the Company does not have any net operating loss carry-forwards in the U.S., the tax benefit reduces income taxes payable in the current year and is therefore recorded to additional paid-in-capital. Accumulated Other Comprehensive Income (Loss) The following table details the accumulated other comprehensive income (loss) activity for the years ended December 31, 2015, 2014, and 2013: (In thousands) Foreign currency Unrealized Unrealized Accumulated other Balance at December 31, 2012 $ 16,126 $ 40 $ - $ 16,166 Other comprehensive income before reclassifications (567 ) 2 - (565 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2013 $ 15,559 $ 42 $ - $ 15,601 Other comprehensive income before reclassifications (351 ) (7 ) (978 ) (1,336 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2014 $ 15,208 $ 35 $ (978 ) $ 14,265 Other comprehensive income before reclassifications (965 ) 7 105 (853 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2015 $ 14,243 $ 42 $ (873 ) $ 13,412

Note 21 - Income Taxes

Note 21 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	21. Income Taxes Income before income taxes for the years ended December 31, 2015, 2014 and 2013 is as follows: Year Ending December 31, 2015 2014 2013 U.S. $ 14,685 $ 18,005 $ 9,175 Foreign 28,990 9,128 1,768 $ 43,675 $ 27,133 $ 10,943 The provision for income taxes consists of the following for the years ended December 31, 2015, 2014 and 2013: Year Ended December 31, (In thousands) 2015 2014 2013 Current tax provision (benefit): U.S. Federal $ 15,678 $ 11,319 $ 5,198 U.S. State 1,810 1,351 1,008 Foreign 2,709 793 (582 ) Total current tax provision 20,197 13,463 5,624 Deferred provision (benefit): U.S. Federal (6,375 ) (172 ) (1,783 ) U.S. State (899 ) (16 ) (279 ) Foreign (2,619 ) 730 366 Total deferred provision (benefit) (9,893 ) 542 (1,696 ) Total income tax provision $ 10,304 $ 14,005 $ 3,928 Deferred tax assets (liabilities), net, consist of the following as of December 31, 2015 and 2014: December 31, 2015 2014 (In thousands) Deferred tax assets: Foreign net operating loss carry-forwards $ 716 $ 1,409 State net operating loss carry-forwards 2 3 Tax credit carry-forwards 976 - Deferred revenue 446 1,803 Accrued expenses 1,450 734 Tax benefits on stock options 3,288 2,063 Research and development credits 1,759 - Inventory - 615 Property and equipment - 15 Other 3,775 207 Gross deferred tax assets 12,412 6,849 Deferred tax liabilities: Property and equipment (654 ) (122 ) Inventory (3,990 ) - Investments (13,963 ) - Intangibles (44,025 ) (4,368 ) Gross deferred tax liabilities (62,632 ) (4,490 ) Less: valuation allowance (2,277 ) (2,132 ) Net deferred tax assets (liabilities) $ (52,497 ) $ 227 The provision for income taxes vary from the income taxes provided based on the federal statutory rate as follows for the three years ended December 31, 2015, 2014 and 2013: Year Ended December 31, (In thousands) 2015 2014 2013 Federal tax provision (benefit) 35.0 % 35.0 % 35.0 % State taxes, net of federal tax benefit 0.9 % 2.1 % 4.9 % Foreign tax rate differential -16.8 % 0.0 % 0.0 % Changes in valuation allowance 0.5 % 1.4 % -21.6 % Nondeductible expenses 2.3 % 1.7 % 1.3 % Stock based compensation 0.6 % -0.1 % -2.8 % Impact of intangible transfer 0.7 % 5.8 % 7.3 % Impact of uncertain tax positions 1.8 % -0.2 % -0.1 % Adjustment to deferred tax asset -1.6 % 0.5 % 11.1 % Impact of foreign operations 0.0 % -3.7 % 0.3 % Subpart F income, net of FTC 2.3 % 9.1 % 0.0 % Change in tax rates 0.0 % 0.0 % 0.6 % Loan forgiveness -2.3 % 0.0 % 0.0 % Japanese R&D credit -1.6 % 0.0 % 0.0 % Changes in other tax matters 1.8 % 0.0 % -0.1 % 23.6 % 51.6 % 35.9 % The significant increase in the net deferred tax liability shown above was a result of the R-Tech acquisition in October 2015. Specifically, purchase accounting adjustments to the financial reporting basis of R-Tech assets and liabilities resulted in significant deferred tax liabilities that were recorded during purchase accounting. At December 31, 2015 and 2014, the Company had foreign net operating loss carry-forwards of $2.8 million and $5.9 million, respectively. Approximately $1.0 million of the foreign NOLs begin to expire in December 2019, and $1.8 million of the foreign NOLs do not expire. As of December 31, 2015 and 2014, the Company had no material NOLs in the U.S. As of December 31, 2015 and 2014, the Company had a valuation allowance on its deferred tax assets of $2.3 million and $2.1 million, respectively. The change in the valuation allowance was due to two factors. First, the release of valuation allowance in two foreign jurisdictions and the reversal of existing US GAAP to local GAAP deferred tax assets during the year resulted in a net decrease. In addition, the Company established a valuation allowance for certain tax credit carryforwards that are expected to expire unutilized. The valuation allowance at December 31, 2015 and 2014 relates to deferred tax assets in the foreign jurisdictions and certain tax credit carryforwards in the US. The Company will continue to evaluate its valuation allowance position in each jurisdiction on a regular basis. To the extent the Company determines that all or a portion of its valuation allowance is no longer necessary, the Company will recognize an income tax benefit in the period such determination is made for the reversal of the valuation allowance. Once the valuation allowance is eliminated in whole or in part, it will not be available to offset the Company’s future tax provision. The Company has recorded a total income tax liability for uncertain tax positions (including interest) of approximately $3.1 million and $0.8 million, as of December 31, 2015 and 2014, respectively. The Company presently does not expect to settle any of this amount within the next twelve months in cash and as such, has reflected the entire balance as other liabilities in the accompanying Consolidated Balance Sheets. The amount represents the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2015 and 2014 mainly pertains to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions. A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the years ended December 31, 2015, 2014 and 2013 is as follows: Year Ended December 31, 2015 2014 2013 Balance at January 1 $ 712 $ 550 $ 979 Increases for tax positions taken during prior periods 452 (91 ) 4 Decreases in unrecognized tax benefits related to taxing authority correspondence (280 ) - (467 ) Increases for tax positions taken during current period 2,108 253 34 Balance at December 31 $ 2,992 $ 712 $ 550 The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. During 2015, 2014 and 2013, the Company recorded an immaterial amount of interest related to uncertain tax positions. Of the unrecognized tax benefits noted above, approximately $1.7 million would impact the effective tax rate if a future change were to occur. It is reasonably possible that the $1.3 million of the liability for unrecognized tax benefits will decrease within the next 12 months. Currently tax years 2011 to 2015 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed. The tax years 2009-2011 were examined by the U.S. tax authorities and resulted in no tax adjustments.

Note 22 - Quarterly Financial D

Note 22 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Quarterly Financial Information [Text Block]	22. Quarterly Financial Data (unaudited) 2015 Quarters Ended (In thousands, except per share data) December 31 September 30 June 30 March 31 Total revenues $ 55,368 $ 33,448 $ 34,884 $ 29,480 Income from operations 11,568 11,657 11,580 9,654 Net income 10,151 7,236 9,576 6,408 Net income per share: Basic $ 0.24 $ 0.16 $ 0.21 $ 0.14 Diluted 0.23 0.16 0.21 0.14 2014 Quarters Ended (In thousands, except per share data) December 31 September 30 June 30 March 31 Total revenues $ 37,757 $ 31,463 $ 24,069 $ 22,161 Income from operations 17,048 3,643 3,811 2,729 Net income 9,283 1,480 1,610 755 Net income per share: Basic $ 0.21 $ 0.03 $ 0.04 $ 0.02 Diluted 0.21 0.03 0.04 0.02 Net income per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly net income per share information may not equal annual net income per share.

Note 23 - Subsequent Events

Note 23 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	23. Subsequent Events On January 11, 2016, the Company entered into an option and collaboration agreement with Cancer Prevention Pharmaceuticals, Inc. (CPP). Under the terms of the agreement, CPP granted the Company the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP). Enrollment in the study is expected to be complete in the first half of 2016 and the trial is expected to conclude in 2018. Under the terms of the agreement, the Company has invested $5.0 million in CPP in the form of a convertible note, with a planned additional $5.0 million equity investment in CPP’s next qualified financing, which will be either an IPO or a private financing, as defined by the agreement. In addition, the Company will pay CPP an option fee of up to $7.5 million, payable in two tranches; the first tranche of $3.0 million was paid at signing. CPP will complete the ongoing Phase 3 trial under the oversight of a joint steering committee. Upon exercise of its exclusive option, the Company would acquire an exclusive license to develop and commercialize the product in North America for all indications and would be obligated to pay CPP up to an aggregate of $190 million in license fees and milestone payments upon the achievement of specified clinical development and sales milestones. Under the terms of the license, the Company and CPP would share equally in profits from the sale of licensed products.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II – Valuation and Qualifying Accounts (In thousands) Balance at Additions Deductions Balance at Allowance for doubtful accounts: 2013 $ 280 $ 160 (a) $ - $ 440 2014 $ 440 $ 364 (a) $ (779 )(b) $ 25 2015 $ 25 $ 29 $ - $ 54 Valuation allowance for deferred tax assets: 2013 $ 4,142 $ - $ (2,391 )(c) $ 1,751 2014 $ 1,751 $ 381 (d) $ - $ 2,132 2015 $ 2,132 $ 1,177 (e) $ (1,032 )(c) $ 2,277 (a) In 2013 and 2014, the increase in allowance for doubtful accounts is associated with certain disputed Takeda invoices. (b) In 2014 the deduction from allowance for doubtful accounts resulted from a charge-off of certain disputed Takeda invoices. (c) In 2013 and 2015, the net decrease in valuation allowance for deferred tax assets of $2.4 million and $1.0 million, respectively, was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent in 2013 for anticipated liquidation. (d) The net increase of $381,000 was primarily due to the additional NOL’s in foreign jurisdictions where management believes it is more likely than not a portion of the NOL balance will expire prior to utilization. (e) In 2015, the net increase in the valuation allowance of $1.2 million was a result of the accrual of tax credit carryforwards that are expected to expire prior to utilization.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America, (GAAP) and the rules and regulations of the Securities and Exchange Commission, (SEC). The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd. (acquired October 20, 2015), based in Kobe, Japan through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America and Sucampo Pharma Europe, Ltd., based in Oxford, U.K.. All inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of Sucampo Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expense during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For the purpose of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase.
Investment, Policy [Policy Text Block]	Current and Non-Current Investments Current and non-current investments consist primarily of U.S. government agency securities, certificates of deposit, corporate bonds, municipal securities and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available-for-sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable Accounts receivable primarily represents amounts due under the North America Takeda Agreement and Japan Mylan Agreement. The Company recorded an immaterial allowance for doubtful accounts at December 31, 2015 and 2014. Accounts receivable of zero and $779,000 were charged off against the allowance for doubtful accounts during the years ended December 31, 2015 and 2014, respectively.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out convention. Inventories consist of raw material, work-in-process and finished goods. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash As of December 31, 2015, restricted cash consisted primarily of $25.0 million related to the Credit Facility that requires the Company to maintain $25.0 million in a restricted cash account until at least $35 million of the Term Loans have been repaid or prepaid (see note 17). Further, as part of the R-Tech acquisition, $17.7 million is held in a restricted cash account for payment of the Ueno and Kuno Trust Notes, which were settled on February 1, 2016 (see note 17), and $8.2 million is held in restricted cash related to the squeeze out of non-tendering R-Tech shareholders, which was settled in January, 2016. Restricted cash at December 31, 2014 primarily represented collateral pledged to support a loan guarantee and development agreement (Numab Agreement) between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled $2.4 million at December 31, 2014.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and consist of computer and office machines, furniture and fixtures, IT infrastructure and leasehold improvements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in earnings.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of December 31, 2015 and 2014, approximately $5.9 million, or 3.6%, and $37.0 million, or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or other government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 63.3%, 71.3% and 81.3% of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013, respectively. Accounts receivable and product royalties receivable from Takeda accounted for 78.1% and 88.5% of the Company’s total accounts receivable and product royalties receivable at December 31, 2015 and 2014. Revenues from another unrelated party, Mylan, accounted for 35.2%, 27.8% and 17.6% of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013. The Company depends significantly upon collaborations with Takeda and Mylan, and its activities may be impacted if these relationships are disrupted (see note 19).
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying values of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable, collaboration obligation and accrued expenses. The carrying amounts of the Notes (as defined below) at December 31, 2015 and 2014 did approximate fair value and are classified as a Level 2 instrument.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company’s revenues are derived primarily from product royalties, product sales, development milestone payments, clinical development activities, and contract and collaboration activities. Multiple-Element Arrangements The Company evaluated the multiple deliverables within the AMITIZA agreements in accordance with the guidance of multiple deliverables under ASC 605-25 “ Revenue Recognition — Multiple-Element Arrangements” Where agreements include contingent milestones the Company evaluates whether each milestone is substantive. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Where milestones are not considered substantive their treatment is based on either a time-based or proportional performance model. Research and Development Revenue The Company applied a time-based model of revenue recognition for cash flows associated with research and development deliverables agreed upon prior to January 1, 2011 under the North America Takeda Agreement. Under this model, cash flow streams related to each unit of accounting are recognized as revenue over the estimated performance period. Upon receipt of cash payments, such as development milestones, revenue is recognized to the extent the accumulated service time has occurred. The remainder is deferred and recognized as revenue ratably over the remaining estimated performance period. For research and development deliverables agreed upon subsequent to January 1, 2011 under the North America Takeda agreement, which are reimbursable by Takeda at contractually predetermined percentages, the Company recognizes revenue when the underlying research and development expenses are incurred, assuming all other revenue recognition criteria are met. Product Royalty Revenue Product royalty revenue represents royalty revenue earned on Takeda’s net sales of AMITIZA under the North America Takeda Agreement, and is recorded when earned in accordance with the contractual terms, collectability is reasonably assured and all other revenue recognition criteria are met. Product Sales Revenue Product sales revenue consists of AMITIZA sales under the Japan Mylan Agreement, the North America Takeda Agreement, Global Takeda Agreement, and prior to the Global Takeda Agreement, by the Company in Europe, and RESCULA sales to Santen in Japan and by the Company in the U.S. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return. Co-promotion Revenue Takeda reimbursements of co-promotion costs under the North America Takeda Agreement, including costs associated with the Company’s specialty sales force and miscellaneous marketing activities, are recognized as co-promotion revenue as the related costs are incurred and Takeda becomes contractually obligated to pay the amounts. The Company has determined that it is acting as a principal under this agreement, and as such, records reimbursements of these amounts on a gross basis as co-promotion revenue. In December 2014, the Company ceased co-promoting AMITIZA as a result of the amendment to the North America Takeda Agreement. Contract and Collaboration Revenue Contract and Collaboration revenue relates to development and consulting activities and includes $8.0 million of the upfront payment received from Takeda in 2014 under the Global Takeda Agreement. The Company considers its participation in joint committees under the Japan Mylan Agreement and North America Takeda Agreement as separate deliverables under the contracts and recognizes the best estimate of selling price of such participation as collaboration revenue over the period of the participation per the terms of the contracts. Deferred Revenue Deferred revenue represents payments received for licensing fees, option fees, consulting, research and development contracts and related cost sharing and supply agreements, mainly with Takeda and Mylan, which are deferred until revenue can be recognized under the Company’s revenue recognition policy. At December 31, 2015 and 2014, total deferred revenue was approximately $1.8 million and $7.2 million, respectively. Total deferred revenue consists of the following as of: December 31, (In thousands) 2015 2014 Deferred revenue, current $ 676 $ 2,051 Deferred revenue, non-current 1,088 5,118 $ 1,764 $ 7,169 Deferred revenue to related parties, included in total deferred revenue: Deferred revenue to related parties, current $ - $ 453 Deferred revenue to related parties, non-current - 4,141 Total $ - $ 4,594 During the fourth quarter of 2015, as part of the R-Tech acquisition, the Company recognized $3.9 million of deferred revenue as part of settlement of a pre-existing relationship with R-Tech.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company estimates the fair value of share-based payment awards on the date of the grant using an option-pricing model and recognizes the expense over the required service periods. For recording of the stock-based compensation expense for service based and market condition options, the Company has chosen to use: · the straight-line method of allocating compensation cost for service based options and graded vesting for market condition options; · the Black-Scholes-Merton option pricing formula for time based options and the Monte Carlo simulation model for the market condition options as the Company’s chosen option-pricing models; · the simplified method to calculate the expected term for options as discussed under the SEC’s guidance for share-based payments for service based options; · an estimate of expected volatility based on the historical volatility of the Company’s share price; and · an estimate for expected forfeitures. The three factors which most affect stock-based compensation are the fair value of the common stock underlying the stock options, the vesting term of the options, and the volatility of such fair value of the underlying common stock. If the Company’s estimates are too high or too low, the Company may overstate or understate its stock-based compensation expense.
Pension and Other Postretirement Plans, Policy [Policy Text Block]	Pension The Company utilizes actuarial methods to measure the benefit obligations and net periodic pension cost/income for its Swiss pension plan. Inherent in the application of these actuarial methods are key assumptions, including, but not limited to, discount rates, mortality rates, and rates of compensation increases. Company management evaluates these assumptions annually and updates assumptions as necessary. Net actuarial gains or losses are amortized to expense in future periods over the average future service period for employees of plans. The fair values of assets are determined based on the sum of the saving capitals of the actives in the pension plan.
Business Combinations Policy [Policy Text Block]	Mergers and Acquisitions In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the merger or acquisition at their respective fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect our intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of the merger or acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. The fair values of intangible assets, including acquired in-process research and development (IPR&D) are determined utilizing information available near the merger or acquisition date based on expectations and assumptions of a market participant that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Amounts allocated to acquire IPR&D are capitalized and accounted for as indefinite-lived intangible assets. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company's results of operations. The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an "income approach" through which fair value is estimated based on each asset's discounted projected net cash flows. Our estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company's competitors; and the life of each asset's underlying patent, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate. The fair values of identifiable intangible assets related to IPR&D are determined using an income or cost approach. Under the income approach fair value is estimated based on each asset’s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using appropriate discounts. Under the replacement cost approach, historical research and development spending is analyzed to derive the costs incurred to date related to the asset. An expected return of 20% was applied to the cumulative research and development costs incurred to date, as this estimates the required rate of a return a prudent investor would require on a similarly situated asset. No tax amortization benefit is applied given the asset is valued under the replacement cost approach, which is representative of buying the asset in the market at fair value.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recognized. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital. The Company also evaluates goodwill using the qualitative assessment method, which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected the fair value of the reporting unit since the date of the most recent quantitative analysis of a reporting unit's fair value. As described in note 4 to these consolidated financial statements, the Company operates as one operating segment which is considered our only reporting unit. The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1 as its annual impairment test date.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses from third parties who conduct research and development activities pursuant to development and consulting agreements on behalf of the Company. Costs related to the acquisition of intellectual property are expensed as incurred in research and development expenses since the underlying technology associated with such acquisitions is unproven, has not received regulatory approval at its early stage of development and does not have alternative future uses. Milestone payments due under agreements with third party contract research organizations (CROs) are accrued when it is considered probable that the milestone event will be achieved.
Accrued Research and Development Expenses [Policy Text Block]	Accrued Research and Development Expenses As part of the process of preparing Consolidated Financial Statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company’s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external CROs and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment; invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes significant judgments and estimates in determining the accrued balance in any accounting period. No material adjustments have been required for this accrual during the years ended December 31, 2015 and 2014.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with the relevant accounting guidance for income taxes. Under the asset and liability method, the current income tax provision or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in the income tax provision during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carry-forwards that can be utilized in the future to offset taxable income. The Company’s discussion of income tax is described more fully under note 21 found below. In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the U.S. based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. As of December 31, 2015, 2014 and 2013, the total deferred charge is $1.7 million, $2.0 million and $5.2 million, respectively, after a net current year amortization and impairment expense of $0.3 million, $3.2 million and $0.7 million, respectively. Impairment expense included in the $3.2 million for 2014 totaled $1.8 million and resulted from the cessation of direct commercialization activities for RESCULA in 2014. For all significant intercompany transactions, the Company’s management has evaluated the terms of the transactions using significant estimates and judgments to ensure that each significant transaction would be on similar terms if the Company completed the transaction with an unrelated party. Although the Company believes there will be no material tax liabilities to the Company as a result of multi-jurisdictional transactions, there can be no assurance that taxing authorities will not assert that transactions were entered into at monetary values other than fair values. If such assertions were made, the Company’s intention would be to vigorously defend its positions; however, there can be no assurance that additional liabilities may not occur as a result of any such assertions. The Company considers certain undistributed earnings of foreign subsidiaries to be indefinitely reinvested outside of the U.S. and, accordingly, no U.S. deferred taxes have been recorded under the applicable accounting standard with respect to such earnings. Should the earnings be remitted to the U.S., the Company may be subject to additional U.S. taxes, net of allowable foreign tax credits. It is not practicable to estimate the amount of any additional taxes which may be payable on the undistributed earnings.
Income Tax Uncertainties, Policy [Policy Text Block]	Uncertain Tax Positions The Company applies the accounting guidance for uncertain tax positions that requires the application of a more likely than not threshold to the recognition and de-recognition of uncertain tax positions. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement. The Company has recorded an income tax liability of approximately $2.9 million and $0.8 million, including interest, for uncertain tax positions as of December 31, 2015 and 2014, respectively. As of December 31, 2015, the entire balance was reflected as other liabilities in the accompanying Consolidated Balance Sheets. As of December 31, 2014, $0.3 million and $0.6 million are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. These amounts represent the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. It is reasonably possible that the $1.3 million of the liability for unrecognized tax benefits will decrease within the next 12 months. In addition, future changes in the unrecognized tax benefits would have an effect on the effective tax rate when recognized. Currently, tax years 2011 to 2015 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The functional currency for most of the Company’s foreign subsidiaries is its local currency. For the Company’s non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency is the U.S. dollar, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in net income. Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income.
Comprehensive Income, Policy [Policy Text Block]	Other Comprehensive Income Comprehensive income consists of net income plus certain other items that are recorded directly to stockholders’ equity. The Company has reported comprehensive income in the Consolidated Statements of Operations and Comprehensive Income. The Company has outstanding intercompany loans and investments between its subsidiaries which are eliminated for purposes of the Consolidated Financial Statements. These intercompany loans are not expected to be repaid or settled in the foreseeable future. Accordingly, the currency transaction gains or losses on these intercompany loans are recorded as part of other comprehensive income in the Consolidated Financial Statements. In addition, the actuarial gains and losses of the Swiss Pension plan are recorded in comprehensive income.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued new guidance related to accounting for leases. The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. For leases with a term of 12 months or less, a lessee can make an accounting policy election by class of underlying asset to not recognize an asset and corresponding liability. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. These disclosures are intended to supplement the amounts recorded in the financial statements and provide additional information about the nature of an organization’s leasing activities. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The transition guidance also provides specific guidance for sale and leaseback transactions, build-to-suit leases and amounts previously recognized in accordance with the business combinations guidance for leases. We are currently evaluating our expected adoption method and the impact of this new standard on our consolidated financial statements. In January 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In September 2015, the FASB issued Accounting Standards Update 2015-16, Business Combinations (Topic 805) - Simplifying the Accounting for Measurement-Period Adjustments In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In April 2015 Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 will have no effect on the Company’s results of operations or liquidity. In May 2014, the FASB issued authoritative guidance which sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance was originally scheduled to be effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, but in July 2015 the FASB voted to defer the effective date to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is currently evaluating the impact of this guidance on its results of operations, financial position and cash flows.

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	December 31, (In thousands) 2015 2014 Deferred revenue, current $ 676 $ 2,051 Deferred revenue, non-current 1,088 5,118 $ 1,764 $ 7,169 Deferred revenue to related parties, included in total deferred revenue: Deferred revenue to related parties, current $ - $ 453 Deferred revenue to related parties, non-current - 4,141 Total $ - $ 4,594

Note 3 - Net Income Per Share (

Note 3 - Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year To Date December 31, (in thousands, except per share data) 2015 2014 2013 Basic net income per share: Net income $ 33,371 $ 13,128 $ 7,015 Weighted average class A and B common shares outstanding 44,150 43,691 41,716 Basic net income per share $ 0.76 $ 0.30 $ 0.17 Diluted net income per share: Net income $ 33,371 $ 13,128 $ 7,015 Weighted average class A and B common shares outstanding for diluted net income per share 44,150 43,691 41,716 Assumed exercise of stock options under the treasury stock method 1,530 815 828 45,680 44,506 42,544 Diluted net income per share $ 0.73 $ 0.29 $ 0.16
Schedule of Potentially Dilutive Securities [Table Text Block]	December 31, (In thousands) 2015 2014 2013 Employee stock options 3,290 1,124 2,129 Non-employee stock options - 255 410
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, (In thousands) 2015 2014 2013 Employee stock options 1,188 3,012 530

Note 4 - Segment Reporting (Tab

Note 4 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Years Ended December 31, (In thousands) 2015 2014 2013 Product royalty revenue $ 74,138 $ 62,775 $ 52,100 Product sales revenue 66,276 33,252 16,425 Research and development revenue 10,199 7,246 654 Contract and collaboration revenue 2,567 8,817 20,354 Co-promotion revenue - 3,360 61 Total $ 153,180 $ 115,450 $ 89,594
Revenue from External Customers by Geographic Areas [Table Text Block]	Years Ended December 31, (In thousands) 2015 2014 2013 United States $ 95,769 $ 74,688 $ 73,637 Japan 55,371 32,128 15,849 Rest of the world 2,040 8,634 108 Total $ 153,180 $ 115,450 $ 89,594
Long-lived Assets by Geographic Areas [Table Text Block]	December 31, (In thousands) 2015 2014 2013 United States $ 3,105 $ 566 $ 869 Japan 3,232 114 175 Rest of the world 56 83 112 Total $ 6,393 $ 763 $ 1,156

Note 5 - Acquisitions (Tables)

Note 5 - Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	(In thousands) As of October 20, 2015 Cash $ 62,097 Accounts receivable 8,299 Inventory (i) 37,563 Prepaid expenses 3,425 Property, plant and equipment 3,115 Other long term assets 449 Accounts payable and accrued liabilities (11,598 ) Income tax payable (5,025 ) Other liabilities, current (3,282 ) Deferred tax liability, net (62,927 ) Other liabilities, long term (9,347 ) R-Tech shares of Sucampo stock (treasury stock) 43,956 Total fair value of tangible assets acquired and liabilities assumed 66,725 Acquired in-process research and development 6,200 Acquired intangible assets 134,600 Goodwill 61,228 Total purchase price $ 268,753 Total purchase price $ 268,753 Settlement of net receivable from pre-existing relationship 6,364 Total consideration $ 275,117 Acquisition, net of acquired cash $ 161,187 Acquired cash 62,097 Purchase of treasury stock 43,956 Squeeze out liability for non-tendering R-Tech shareholders 7,668 Other 209 Total consideration $ 275,117
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	(In thousands) As of October Amortization Acquired in-process research and development $ 6,200 Indefinite Acquired intangible assets: AMITIZA - manufacturing know-how 120,200 14 RESCULA - manufacturing know-how 14,400 10 $ 134,600
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended December 31, (In thousands) 2015 2014 Pro forma revenue $ 199,462 $ 151,527 Pro forma net income 25,617 (20,031 )

Note 6 - Restructuring (Tables)

Note 6 - Restructuring (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Restructuring and Related Costs [Table Text Block]	(In thousands) Termination Facility Contract & Total Balance at December 31, 2014 $ - $ - $ - $ - Expenses incurred 953 - - 953 Amounts paid (102 ) - - (102 ) Balance at December 31, 2015 $ 851 $ - $ - $ 851

Note 7 - Current and Non-Curr37

Note 7 - Current and Non-Current Investments (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Available-for-sale Securities [Table Text Block]	December 31, 2014 (In thousands) Cost Unrealized Unrealized Fair Value Current: U.S. government agencies $ 4,203 $ 1 $ - $ 4,204 Certificates of deposit 2,500 - - 2,500 Corporate bonds 4,575 - (3 ) 4,572 U.S. commercial paper 11,109 8 - 11,117 Total $ 22,387 $ 9 $ (3 ) $ 22,393 Non-current: U.S. government agencies $ 8,047 $ - $ (15 ) $ 8,032 Certificates of deposit 5,000 5,000 Corporate bonds 509 - (1 ) 508 Total $ 13,556 $ - $ (16 ) $ 13,540

Note 9 - Inventories (Tables)

Note 9 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, (In thousands) 2015 Raw materials $ 5,554 Work in process 26,926 Finished goods 641 Total $ 33,121

Note 10 - Property and Equipm39

Note 10 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (In thousands) 2015 2014 Computer and office machines $ 2,647 $ 2,622 Furniture and fixtures 1,023 473 Leasehold improvements 3,066 1,415 Buildings 1,022 - Machinery and equipment 2,074 - Construction in progress 140 - Total cost 9,972 4,510 Less: accumulated depreciation (3,579 ) (3,747 ) Total $ 6,393 $ 763

Note 11 - Intangible Assets, 40

Note 11 - Intangible Assets, In-process Research and Development and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	December 31, 2015 December 31, 2014 (In thousands) Weighted Carrying Weighted Carrying Amortized intangible assets Patent and license rights 72 $ 10,513 84 $ 10,513 Manufacturing know how 76 134,600 - Accumulated amortization (8,463 ) (4,711 ) Impairment losses (5,651 ) (5,651 ) Foreign currency translation adjustments (684 ) - Total amortized intangible assets $ 130,315 $ 151 Unamortized intangible assets In-process research and development $ 6,171 $ - Goodwill 60,937 - Total unamortized intangible assets $ 67,108 $ - Total intangible assets $ 197,423 $ 151
Schedule of Changes in Intangible Assets and Goodwill [Table Text Block]	(In thousands) Intangibles Goodwill In-process Balance at December 31, 2013 $ 6,438 $ - $ - Amortization (636 ) - - Impairment losses (5,651 ) - - Balance at December 31, 2014 $ 151 $ - $ - Additions 134,600 61,228 6,200 Amortization (3,752 ) - - Foreign currency translation adjustment (684 ) (291 ) (29 ) Balance at December 31, 2015 $ 130,315 $ 60,937 $ 6,171
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) Amortization Years ended December 31, 2016 $ 22,689 2017 22,689 2018 22,689 2019 22,689 2020 22,689

Note 12 - Accrued Expenses (Tab

Note 12 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, (In thousands) 2015 2014 Research and development costs $ 3,843 $ 3,537 Employee compensation 4,860 3,459 Restructuring 851 - Selling and marketing costs 1 163 Legal service fees 428 612 Other accrued expenses 903 696 Total $ 10,886 $ 8,467

Note 14 - Other Current Liabi42

Note 14 - Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Other Current Liabilities [Table Text Block]	December 31, (In thousands) 2015 2014 Indirect taxes payable 5,963 3,075 Squeeze out liability for non-tendering R-Tech shareholders 7,668 - Other current liabilities 508 543 Total $ 14,139 $ 3,618

Note 15 - Other Liabilities (Ta

Note 15 - Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Other Noncurrent Liabilities [Table Text Block]	December 31, (In thousands) 2015 2014 Deferred grants $ 9,604 $ - Unrecognized tax benefits 3,061 - Deferred leasehold incentive 1,715 380 Defined benefit obligation 949 977 Other liabilities 414 579 Total $ 15,743 $ 1,936
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	Reconciliation of Projected Benefit Obligation December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation at beginning of year $ 2,760 $ 1,708 Service cost 164 191 Interest cost 28 43 Plan participants’ contributions 90 165 Plan amendments (39 ) - Actuarial loss (gain) - 653 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Projected benefit obligation at end of year $ 2,513 $ 2,769 Reconciliation of Fair Value of Plan Assets December 31, 2015 December 31, 2014 (in thousands) Fair value of plan assets at beginning of year $ 1,787 $ 1,342 Actual return on plan assets 42 42 Employer contribution 136 234 Plan participants’ contributions 90 165 Benefits paid (436 ) 83 Expenses Paid (5 ) (8 ) Premiums Paid (49 ) (66 ) Fair value of plan assets at end of year $ 1,565 $ 1,792 Funded status at end of year $ (948 ) $ (977 )
Schedule of Reconciliation of Amounts Recognized in Consolidated Statements of Operations and Comprehensive Income [Table Text Block]	Reconciliation of amounts recognized in Consolidated Statements of Operations and Comprehensive Income Year ended Year ended (in thousands) Net loss $ (862 ) $ (978 ) Total amount recognized in accumulated other comprehensive income $ (862 ) $ (978 ) Accumulated contributions in excess of net periodic benefit cost (87 ) 1 Funded status at end of year $ (949 ) $ (977 )
Schedule of Net Benefit Costs [Table Text Block]	Net periodic pension cost included the following components Year ended Year ended (in thousands) Service cost $ 164 $ 191 Interest cost 28 43 Expected return on assets (39 ) (30 ) Amortization of unrecognized net loss 73 17 Net periodic pension cost $ 226 $ 221
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	Changes in plan assets and benefit obligations recognized in other comprehensive income Year ended Year ended (in thousands) New prior service cost $ (39 ) $ - Net loss arising during year (2 ) 641 Amortization or settlement of net loss (73 ) (17 ) Total recognized in other comprehensive income $ (114 ) $ 624 Total loss recognized in net periodic cost and other comprehensive income $ 111 $ 845
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	Estimated amounts to be amortized from accumulated other comprehensive income over the next year December 31, 2015 December 31, 2014 (in thousands) Net loss $ 76 $ 73
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	Additional year-end information for plans with projected benefit obligations in excess of plan assets December 31, 2015 December 31, 2014 (in thousands) Projected benefit obligation $ 2,514 $ 2,769 Accumulated benefit obligation 2,233 2,469 Fair value of plan assets 1,566 1,792
Schedule of Allocation of Plan Assets [Table Text Block]	Weighted average allocation of plan assets December 31, 2015 December 31, 2014 Debt Securities 78 % 79 % Real Estate 12 % 12 % Other Investments 8 % 6 % Cash 2 % 3 % Total 100 % 100 %
Schedule of Assumptions Used [Table Text Block]	Weighted average assumptions used to determine net periodic pension cost Year ended Year ended Discount or settlement rates 1.0 % 2.5 % Expected long-term rates of return on assets 2.1 % 2.1 % Rates of increase in compensation levels 1.5 % 1.5 %
Schedule of Expected Benefit Payments [Table Text Block]	Weighted average assumptions used to determine future benefit obligations December 31, 2015 December 31, 2014 Discount rate 0.9 % 1.0 % Rates of increase in compensation levels 1.5 % 1.5 % Expected future cash flows (in thousands) Employee Contributions 2016 $ 155 $ 151 Benefit Payments 2016 7 145 2017 12 10 2018 17 14 2019 23 18 2020 28 23 2021-2025 634 494

Note 16 - Commitments and Con44

Note 16 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(In thousands of U.S. dollars) December 31, 2016 $ 1,781 2017 941 2018 1,233 2019 1,020 2020 966 Total minimum lease payments $ 5,941

Note 17 - Related Party Trans45

Note 17 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Agreements with R-Tech [Member]
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Year Ended December 31, (In thousands) 2015 2014 Deferred revenue, current $ - $ 453 Deferred revenue, non-current - 4,141 $ - $ 4,594
Schedule of Related Party Transactions [Table Text Block]	January 1 Year Ended December 31, (In thousands) 2015 2014 2013 Clinical supplies $ 155 $ 396 $ 827 Other research and development services 347 171 194 Commercial supplies 21,415 15,776 14,902 $ 21,917 $ 16,343 $ 15,923
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	December 31, (In thousands) 2015 2014 Deferred revenue, current $ 676 $ 2,051 Deferred revenue, non-current 1,088 5,118 $ 1,764 $ 7,169 Deferred revenue to related parties, included in total deferred revenue: Deferred revenue to related parties, current $ - $ 453 Deferred revenue to related parties, non-current - 4,141 Total $ - $ 4,594

Note 18 - Notes Payable (Tables

Note 18 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	(In thousands) Amount Years ended December 31, 2016 $ 42,582 2017 25,000 2018 25,000 2019 25,000 2020 25,000

Note 19 - Collaboration and L47

Note 19 - Collaboration and License Agreements (Tables)	12 Months Ended
	Dec. 31, 2015
Mylan [Member]
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Cash Revenue Recognized for the Year Ended Accounts Foreign Amount (In thousands) 2015 Through 2013 2014 2015 2015 Effects 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 846 $ 241 $ 39 $ 34 $ - $ 116 $ 416 Research and development revenue Up-front payment - remainder $ 9,154 $ 9,302 $ - $ - $ - $ (148 ) $ - Development milestone payment 27,500 27,755 - 5,000 5,000 (255 ) - Total $ 36,654 $ 37,057 $ - $ 5,000 $ 5,000 $ (403 ) $ - Product sales revenue $ 96,937 $ 20,830 $ 32,088 $ 48,908 $ 4,958 $ 69 $ -
Takeda [Member]
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Cash Revenue Recognized for the Year Ended December 31, Accounts Amount (In thousands) 2015 Through 2013 2014 2015 2015 (1) 2015 Product royalty revenue $ 405,410 $ 291,427 $ 62,775 $ 74,000 $ 22,792 $ - Product sales revenue $ 996 $ - $ - $ 10,311 $ 9,315 $ - Research and development revenue: Up-front payment - remainder $ 17,624 $ 17,624 $ - $ - $ - $ - Development milestones 140,000 140,000 - - - - Reimbursement of research and development expenses 131,432 116,805 7,221 10,164 2,758 - Total $ 289,056 $ 274,429 $ 7,221 $ 10,164 $ 2,758 $ - Collaboration revenue: Supply agreements - Manufacturing $ 2,337 $ - $ - $ 2,337 $ - $ - Up-front payment associated with the Company's obligation to participate in joint committees $ 2,376 $ 1,346 $ 147 $ 147 $ - $ 736 Total $ 4,713 $ 1,346 $ 147 $ 2,484 $ - $ 736 Co-promotion revenue $ 32,813 $ 29,453 $ 3,360 $ - $ - $ -
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	December 31, (In thousands) 2015 2014 Deferred revenue, current $ 676 $ 2,051 Deferred revenue, non-current 1,088 5,118 $ 1,764 $ 7,169 Deferred revenue to related parties, included in total deferred revenue: Deferred revenue to related parties, current $ - $ 453 Deferred revenue to related parties, non-current - 4,141 Total $ - $ 4,594

Note 20 - Stockholders' Equity

Note 20 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2015 2014 2013 Expected volatility 54% - 70% 70% - 72% 65% - 75% Risk-free interest rate 1.34% - 1.93% 1.63% - 2.01% 1.23% - 1.40% Expected term (in years) 5.28 - 6.25 5.28 - 6.25 5.50 - 6.25 Expected dividend yield 0% 0% 0%
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Year Ended December 31, (In thousands) 2015 2014 2013 Research and development expense $ 2,165 $ 349 $ 293 General and administrative expense 5,053 1,816 1,260 Selling and marketing expense 131 122 191 Total 7,349 2,287 1,744
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 255,000 $ 5.85 Options exercised (127,500 ) 5.85 Options expired (127,500 ) 5.85 Options outstanding, December 31, 2015 - $ - Options exercisable, December 31, 2015 - $ - Options vested and expected to vest, December 31, 2015 - $ - Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 113,900 $ 10.00 Options exercised (76,500 ) 10.00 Options outstanding, December 31, 2015 37,400 10.00 0.34 $ 272,646 Options exercisable, December 31, 2015 37,400 10.00 0.34 $ 272,646 Options vested and expected to vest, December 31, 2015 37,400 10.00 0.34 $ 272,646 Shares Weighted Weighted Aggregate Options outstanding, December 31, 2014 4,021,491 $ 6.93 Options granted 1,321,634 15.18 Options exercised (693,077 ) 5.93 Options forfeited (205,516 ) 10.45 Options expired (3,924 ) 4.09 Options outstanding, December 31, 2015 4,440,608 9.37 8.23 $ 35,461,431 Options exercisable, December 31, 2015 1,763,116 7.07 6.89 $ 18,019,310 Options vested and expected to vest, December 31, 2015 3,581,991 8.99 8.02 $ 29,896,200
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	(In thousands) Foreign currency Unrealized Unrealized Accumulated other Balance at December 31, 2012 $ 16,126 $ 40 $ - $ 16,166 Other comprehensive income before reclassifications (567 ) 2 - (565 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2013 $ 15,559 $ 42 $ - $ 15,601 Other comprehensive income before reclassifications (351 ) (7 ) (978 ) (1,336 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2014 $ 15,208 $ 35 $ (978 ) $ 14,265 Other comprehensive income before reclassifications (965 ) 7 105 (853 ) Amounts reclassified from accumulated other comprehensive loss - - - - Balance at December 31, 2015 $ 14,243 $ 42 $ (873 ) $ 13,412

Note 21 - Income Taxes (Tables)

Note 21 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ending December 31, 2015 2014 2013 U.S. $ 14,685 $ 18,005 $ 9,175 Foreign 28,990 9,128 1,768 $ 43,675 $ 27,133 $ 10,943
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, (In thousands) 2015 2014 2013 Current tax provision (benefit): U.S. Federal $ 15,678 $ 11,319 $ 5,198 U.S. State 1,810 1,351 1,008 Foreign 2,709 793 (582 ) Total current tax provision 20,197 13,463 5,624 Deferred provision (benefit): U.S. Federal (6,375 ) (172 ) (1,783 ) U.S. State (899 ) (16 ) (279 ) Foreign (2,619 ) 730 366 Total deferred provision (benefit) (9,893 ) 542 (1,696 ) Total income tax provision $ 10,304 $ 14,005 $ 3,928
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2015 2014 (In thousands) Deferred tax assets: Foreign net operating loss carry-forwards $ 716 $ 1,409 State net operating loss carry-forwards 2 3 Tax credit carry-forwards 976 - Deferred revenue 446 1,803 Accrued expenses 1,450 734 Tax benefits on stock options 3,288 2,063 Research and development credits 1,759 - Inventory - 615 Property and equipment - 15 Other 3,775 207 Gross deferred tax assets 12,412 6,849 Deferred tax liabilities: Property and equipment (654 ) (122 ) Inventory (3,990 ) - Investments (13,963 ) - Intangibles (44,025 ) (4,368 ) Gross deferred tax liabilities (62,632 ) (4,490 ) Less: valuation allowance (2,277 ) (2,132 ) Net deferred tax assets (liabilities) $ (52,497 ) $ 227
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, (In thousands) 2015 2014 2013 Federal tax provision (benefit) 35.0 % 35.0 % 35.0 % State taxes, net of federal tax benefit 0.9 % 2.1 % 4.9 % Foreign tax rate differential -16.8 % 0.0 % 0.0 % Changes in valuation allowance 0.5 % 1.4 % -21.6 % Nondeductible expenses 2.3 % 1.7 % 1.3 % Stock based compensation 0.6 % -0.1 % -2.8 % Impact of intangible transfer 0.7 % 5.8 % 7.3 % Impact of uncertain tax positions 1.8 % -0.2 % -0.1 % Adjustment to deferred tax asset -1.6 % 0.5 % 11.1 % Impact of foreign operations 0.0 % -3.7 % 0.3 % Subpart F income, net of FTC 2.3 % 9.1 % 0.0 % Change in tax rates 0.0 % 0.0 % 0.6 % Loan forgiveness -2.3 % 0.0 % 0.0 % Japanese R&D credit -1.6 % 0.0 % 0.0 % Changes in other tax matters 1.8 % 0.0 % -0.1 % 23.6 % 51.6 % 35.9 %
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2015 2014 2013 Balance at January 1 $ 712 $ 550 $ 979 Increases for tax positions taken during prior periods 452 (91 ) 4 Decreases in unrecognized tax benefits related to taxing authority correspondence (280 ) - (467 ) Increases for tax positions taken during current period 2,108 253 34 Balance at December 31 $ 2,992 $ 712 $ 550

Note 22 - Quarterly Financial50

Note 22 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Quarterly Financial Information [Table Text Block]	2015 Quarters Ended (In thousands, except per share data) December 31 September 30 June 30 March 31 Total revenues $ 55,368 $ 33,448 $ 34,884 $ 29,480 Income from operations 11,568 11,657 11,580 9,654 Net income 10,151 7,236 9,576 6,408 Net income per share: Basic $ 0.24 $ 0.16 $ 0.21 $ 0.14 Diluted 0.23 0.16 0.21 0.14 2014 Quarters Ended (In thousands, except per share data) December 31 September 30 June 30 March 31 Total revenues $ 37,757 $ 31,463 $ 24,069 $ 22,161 Income from operations 17,048 3,643 3,811 2,729 Net income 9,283 1,480 1,610 755 Net income per share: Basic $ 0.21 $ 0.03 $ 0.04 $ 0.02 Diluted 0.21 0.03 0.04 0.02

Schedule II - Valuation and Q51

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Summary of Valuation Allowance [Table Text Block]	(In thousands) Balance at Additions Deductions Balance at Allowance for doubtful accounts: 2013 $ 280 $ 160 (a) $ - $ 440 2014 $ 440 $ 364 (a) $ (779 )(b) $ 25 2015 $ 25 $ 29 $ - $ 54 Valuation allowance for deferred tax assets: 2013 $ 4,142 $ - $ (2,391 )(c) $ 1,751 2014 $ 1,751 $ 381 (d) $ - $ 2,132 2015 $ 2,132 $ 1,177 (e) $ (1,032 )(c) $ 2,277

Note 1 - Business Organizatio52

Note 1 - Business Organization and Basis of Presentation (Details Textual) - USD ($)	1 Months Ended		2 Months Ended	12 Months Ended
	Jun. 30, 2015	May. 31, 2015	Jun. 30, 2015	Dec. 31, 2015
Gloria [Member] | First Tranche [Member] | China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment		$ 1,000,000
Gloria [Member] | Second Tranche [Member] | China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment	$ 500,000
Gloria [Member] | China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment			$ 1,500,000	$ 1,500,000
Takeda [Member] | Lubiprostone Alternate Formulation [Member]
Additional Reformulation Costs Funded, Percentage				100.00%
Takeda [Member] | Lubiprostone for Pediatric Functional Constipation [Member]
Additional Reformulation Costs Funded, Percentage				70.00%

Note 2 - Summary of Significa53

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earliest Tax Year [Member]
Open Tax Year		2,011
Latest Tax Year [Member]
Open Tax Year		2,015
Credit Facility [Member] | Term Loans [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance	$ 25,000,000	$ 25,000,000
Debt Instrument, Covenant, Restricted Cash Account, Balance, Loan Repaid or Prepaid, Amount		35,000,000
Subordinated Unsecured Promissory Notes [Member] | R-Tech [Member] | Kuno and Ueno Trust [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance	17,700,000	17,700,000
R-Tech [Member] | Non-tendering R-tech Shareholders [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance	8,200,000	$ 8,200,000
R-Tech [Member]
Deferred Revenue, Revenue Recognized	3,900,000
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Takeda [Member]
Concentration Risk, Percentage		63.30%	71.30%	81.30%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Mylan [Member]
Concentration Risk, Percentage		35.20%	27.80%	17.60%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Takeda [Member]
Concentration Risk, Percentage		78.10%	88.50%
In Process Research and Development [Member]
Fair Value Assumptions, Intangible Assets, Expected Return on Costs Incurred		20.00%
RESCULA [Member]
Amortization and Impairment of Deferred Charges			$ 1.80
Other Liabilities [Member]
Liability for Uncertain Tax Positions, Noncurrent	2,900,000	$ 2,900,000	600,000
Liability for Uncertain Tax Positions Current and Non-current			800,000
Other Current Liabilities [Member]
Liability for Uncertain Tax Positions, Current			300,000
New Accounting Pronouncement, Early Adoption, Effect [Member] | Reclassification from Current Deferred Tax Assets to Non-current Deferred Tax Liabilities [Member] | Pro Forma [Member]
Prior Period Reclassification Adjustment		500,000
New Accounting Pronouncement, Early Adoption, Effect [Member] | Pro Forma [Member]
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent			1,000,000
Deferred Tax Liabilities, Net, Noncurrent			800,000
Allowance for Doubtful Accounts Receivable, Write-offs		0	779,000
Restricted Cash and Cash Equivalents			2,400,000
Cash, FDIC Insured Amount	$ 5,900,000	$ 5,900,000	$ 37,000,000
Percentage of Deposit within Federally Insured Limits	3.60%	3.60%	33.60%
Revenue Recognition, Milestone Method, Revenue Recognized			$ 8,000,000
Deferred Revenue	$ 1,764,000	$ 1,764,000	7,169,000
Deferred Costs	1,700,000	1,700,000	2,000,000	$ 5,200,000
Amortization and Impairment of Deferred Charges		300,000	$ 3.20	$ 0.70
Liability for Uncertain Tax Positions, Noncurrent	3,061,000	3,061,000
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	1,300,000	1,300,000
Deferred Tax Liabilities, Net, Noncurrent	$ 52,497,000	$ 52,497,000	$ 820,000

Note 2 - Deferred Revenue (Deta

Note 2 - Deferred Revenue (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Related Parties [Member]
Deferred revenue, current		$ 453,000
Deferred Revenue, Noncurrent		4,141,000
		4,594,000
Deferred Revenue		4,594,000
Deferred revenue, current	$ 676,000	2,051,000
Deferred Revenue, Noncurrent	1,088,000	5,118,000
	1,764,000	7,169,000
Deferred Revenue	$ 1,764,000	$ 7,169,000

Note 3 - Net Income (Loss) per

Note 3 - Net Income (Loss) per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Basic net income per share:
Net income	$ 10,151	$ 7,236	$ 9,576	$ 6,408	$ 9,283	$ 1,480	$ 1,610	$ 755	$ 33,371	$ 13,128	$ 7,015
Basic (in shares)									44,150	43,691	41,716
Basic net income per share (in dollars per share)	$ 0.24	$ 0.16	$ 0.21	$ 0.14	$ 0.21	$ 0.03	$ 0.04	$ 0.02	$ 0.76	$ 0.30	$ 0.17
Diluted net income per share:
Net income	$ 10,151	$ 7,236	$ 9,576	$ 6,408	$ 9,283	$ 1,480	$ 1,610	$ 755	$ 33,371	$ 13,128	$ 7,015
Basic (in shares)									44,150	43,691	41,716
Assumed exercise of stock options under the treasury stock method (in shares)									1,530	815	828
(in shares)									45,680	44,506	42,544
Diluted net income per share (in dollars per share)	$ 0.23	$ 0.16	$ 0.21	$ 0.14	$ 0.21	$ 0.03	$ 0.04	$ 0.02	$ 0.73	$ 0.29	$ 0.16

Note 3 - Potentially Dilutive S

Note 3 - Potentially Dilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Assumed exercise of stock options under the treasury stock method (in shares)	3,290	1,124	2,129
Non-Employee Stock Options [Member]
Assumed exercise of stock options under the treasury stock method (in shares)		255	410
Assumed exercise of stock options under the treasury stock method (in shares)	1,530	815	828

Note 3 - Antidilutive Securitie

Note 3 - Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Options [Member]
Employee stock options (in shares)	1,188	3,012	530

Note 4 - Segment Reporting (Det

Note 4 - Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2015
Number of Operating Segments	1

Note 4 - Revenues by Product Ca

Note 4 - Revenues by Product Catergory (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Royalty Revenue									$ 74,138	$ 62,775	$ 52,100
Sales Revenue, Goods, Net									66,276	33,252	16,425
Research and development revenue									10,199	7,246	20,354
Contract and collaboration revenue									$ 2,567	8,817	654
Co-promotion Revenue										3,360	61
Total	$ 55,368	$ 33,448	$ 34,884	$ 29,480	$ 37,757	$ 31,463	$ 24,069	$ 22,161	$ 153,180	$ 115,450	$ 89,594

Note 4 - Revenues by Geographic

Note 4 - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
UNITED STATES
Total	$ 95,769	$ 74,688	$ 73,637
JAPAN
Total	55,371	32,128	15,849
Rest of the World [Member]
Total	2,040	8,634	108
Total	$ 153,180	$ 115,450	$ 89,594

Note 4 - Long-lived Assets by G

Note 4 - Long-lived Assets by Geographic Areas (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
UNITED STATES
United States	$ 3,105,000	$ 566,000	$ 869,000
JAPAN
United States	3,232,000	114,000	175,000
Rest of the World [Member]
United States	56,000	83,000	112,000
United States	$ 6,393,000	$ 763,000	$ 1,156,000

Note 5 - Acquisitions (Details

Note 5 - Acquisitions (Details Textual) ¥ / shares in Units, ¥ in Millions, shares in Millions	Dec. 08, 2015JPY (¥)	Oct. 20, 2015USD ($)	Aug. 31, 2015USD ($)shares	Aug. 31, 2015JPY (¥)	Dec. 31, 2015USD ($)	Aug. 31, 2015USD ($)shares	Aug. 31, 2015JPY (¥)	May. 30, 2016	Dec. 31, 2015USD ($)	Dec. 08, 2015USD ($)	Aug. 31, 2015¥ / shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
R-Tech [Member] | Remaining Outstanding Shares and Stock [Member]
Business Acquisition, Percentage of Voting Interests Acquired			56.00%			56.00%
Business Acquisition, Share Price | ¥ / shares											¥ 1,900
R-Tech [Member] | In Process Research and Development [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 6,200,000				$ 6,200,000
R-Tech [Member] | AMITIZA and RESCULA [Member]
Fair Value Inputs, Discount Rate									18.00%
R-Tech [Member] | Cost of Goods Sold [Member]
Business Acquisition, Amortization Expense					3,700,000				$ 3,700,000
R-Tech [Member] | General and Administrative Expense [Member]
Business Acquisition, Transaction Costs					5,200,000				5,200,000
R-Tech [Member]
Business Acquisition, Percentage of Voting Interests Acquired		98.00%	44.00%			44.00%				2.00%
Business Acquisition, Share Price | ¥ / shares											¥ 1,400
Business Combination, Consideration Transferred	¥ 926	$ 275,117,000	$ 100,000,000	¥ 12,000	7,700,000	$ 175,000,000	¥ 21,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents		62,097,000	$ 62,100,000			$ 62,100,000
Business Combination, Shares of the Acquirer Held by the Acquiree | shares			2.5			2.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Fair Value Adjustment										$ 20,100,000
Business Acquisition, Amortization Period								210 days
Business Acquisition, Additional Cost of Goods Sold Related to Amortization of Set-up Adjustment									$ 5,800,000
Replacement Cost Approach, Expected Return, Rate									20.00%
Business Acquisition, Weighted Average Amortization Period									6 years 180 days
Goodwill		$ 61,228,000			61,200,000				$ 61,200,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									11,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual									4,700,000
Goodwill					$ 60,937,000				$ 60,937,000			$ 0	$ 0

Note 5 - Allocation of the Purc

Note 5 - Allocation of the Purchase Price of Assets a Acquired and Liabilities Assumed (Details) ¥ in Millions	Dec. 08, 2015JPY (¥)	Oct. 20, 2015USD ($)		Aug. 31, 2015USD ($)	Aug. 31, 2015JPY (¥)	Dec. 31, 2015USD ($)	Aug. 31, 2015USD ($)	Aug. 31, 2015JPY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
R-Tech [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents		$ 62,097,000		$ 62,100,000			$ 62,100,000
Accounts receivable		8,299,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory		37,563,000	[1]			$ 14,300,000			$ 14,300,000
Prepaid expenses		3,425,000
Property, plant and equipment		3,115,000
Other long term assets		449,000
Accounts payable and accrued liabilities		(11,598,000)
Income tax payable		(5,025,000)
Other liabilities, current		(3,282,000)
Deferred tax liability, net		(62,927,000)
Other liabilities, long term		(9,347,000)
R-Tech shares of Sucampo stock (treasury stock)		43,956,000
Total fair value of tangible assets acquired and liabilities assumed		66,725,000
Acquired in-process research and development		6,200,000
Acquired intangible assets		134,600,000
Goodwill		61,228,000				61,200,000			61,200,000
Total purchase price		268,753,000
Total purchase price		268,753,000
Settlement of net receivable from pre-existing relationship		6,364,000
Business Combination, Consideration Transferred	¥ 926	275,117,000		$ 100,000,000	¥ 12,000	7,700,000	$ 175,000,000	¥ 21,000
Acquisition, net of acquired cash		161,187,000
Acquired cash		62,097,000
Squeeze out liability for non-tendering R-Tech shareholders		7,668,000
Other		$ 209,000
Goodwill						60,937,000			60,937,000	$ 0	$ 0
Acquisition, net of acquired cash									161,187,000
Squeeze out liability for non-tendering R-Tech shareholders						$ 7,668,000			$ 7,668,000
[1]	Acquired inventory includes a $20.1 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $20.1 million step-up adjustment will amortize evenly through costs of goods sold over a seven month period beginning in November 2015 and ending in May 2016, in alignment with expected inventory turnover. The amortization of the inventory step-up adjustment will increase costs of goods sold during these periods. For the year ended December 31, 2015, the Company recognized $5.8 million in additional costs of goods sold related to the amortization of the inventory step-up adjustment.

Note 5 - Intangible Assets Info

Note 5 - Intangible Assets Information (Details) - R-Tech [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Oct. 20, 2015
AMITIZA [Member]
Acquired intangible assets		$ 120,200
RESCULA [Member]
Acquired intangible assets		14,400
Amortized intangible assets, weighted average life	10 years
AMITIZA [Member]
Amortized intangible assets, weighted average life	14 years
Acquired in-process research and development		6,200
Acquired intangible assets		$ 134,600

Note 5 - Pro Forma Information

Note 5 - Pro Forma Information (Details) - R-Tech [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Pro forma revenue	$ 199,462	$ 151,527
Pro forma net income	$ 25,617	$ (20,031)

Note 6 - Restructuring (Details

Note 6 - Restructuring (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Restructuring Charges	$ 953,000	$ 953,000
Restructuring Reserve	$ 851,000	$ 851,000	$ 0

Note 6 - Cash Components of Res

Note 6 - Cash Components of Restructuring Costs (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015
One-time Termination Benefits [Member]
Balance		$ 0
Restructuring Charges		953,000
Amounts paid		(102,000)
Balance	$ 851,000	851,000
Facility Closing [Member]
Balance		0
Restructuring Charges		0
Amounts paid		0
Balance	0	0
Contract Termination [Member]
Balance		0
Restructuring Charges		0
Amounts paid		0
Balance	0	0
Balance		0
Restructuring Charges	953,000	953,000
Amounts paid		(102,000)
Balance	$ 851,000	$ 851,000

Note 7 - Current and Non-Curr68

Note 7 - Current and Non-Current Investments (Details Textual)	Dec. 31, 2015USD ($)
Available-for-sale Securities	$ 0

Note 7 - Summary of Current and

Note 7 - Summary of Current and Non-Current Investments (Details)	Dec. 31, 2014USD ($)
Current [Member] | US Government Agencies Debt Securities [Member]
Cost	$ 4,203,000
Available-for-sale Securities	4,204,000
Current [Member] | Certificates of Deposit [Member]
Cost	2,500,000
Available-for-sale Securities	2,500,000
Current [Member] | Corporate Bond Securities [Member]
Cost	4,575,000
Available-for-sale Securities	4,572,000
Unrealized Losses	(3,000)
Current [Member] | Commercial Paper [Member]
Cost	11,109,000
U.S. government agencies	8,000
Available-for-sale Securities	11,117,000
Current [Member]
Cost	22,387,000
U.S. government agencies	9,000
Available-for-sale Securities	22,393,000
Unrealized Losses	(3,000)
Non-current [Member] | US Government Agencies Debt Securities [Member]
Cost	8,047,000
Available-for-sale Securities	8,032,000
Unrealized Losses	(15,000)
Non-current [Member] | Certificates of Deposit [Member]
Cost	5,000,000
Available-for-sale Securities	5,000,000
Non-current [Member] | Corporate Bond Securities [Member]
Cost	509,000
Available-for-sale Securities	508,000
Unrealized Losses	(1,000)
Non-current [Member]
Cost	13,556,000
Available-for-sale Securities	13,540,000
Unrealized Losses	(16,000)
US Government Agencies Debt Securities [Member] | Current [Member]
U.S. government agencies	$ 1,000

Note 9 - Inventories (Details T

Note 9 - Inventories (Details Textual) - USD ($)	Dec. 31, 2015	Oct. 20, 2015	[1]	Dec. 31, 2014
R-Tech [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 14,300,000	$ 37,563,000
Inventory, Net	$ 33,121,000			$ 0
[1]	Acquired inventory includes a $20.1 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $20.1 million step-up adjustment will amortize evenly through costs of goods sold over a seven month period beginning in November 2015 and ending in May 2016, in alignment with expected inventory turnover. The amortization of the inventory step-up adjustment will increase costs of goods sold during these periods. For the year ended December 31, 2015, the Company recognized $5.8 million in additional costs of goods sold related to the amortization of the inventory step-up adjustment.

Note 9 - Inventory Components (

Note 9 - Inventory Components (Details)	Dec. 31, 2015USD ($)
Raw materials	$ 5,554,000
Work in process	26,926,000
Finished goods	641,000
Total	$ 33,121,000

Note 10 - Property and Equipm72

Note 10 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Depreciation	$ 637,000	$ 422,000	$ 512,000

Note 10 - Property and Equipm73

Note 10 - Property and Equipment Summary (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Computer and Office Machines [Member]
Property, Plant and Equipment Gross	$ 2,647,000	$ 2,622,000
Furniture and Fixtures [Member]
Property, Plant and Equipment Gross	1,023,000	473,000
Leasehold Improvements [Member]
Property, Plant and Equipment Gross	3,066,000	$ 1,415,000
Building [Member]
Property, Plant and Equipment Gross	1,022,000
Machinery and Equipment [Member]
Property, Plant and Equipment Gross	2,074,000
Construction in Progress [Member]
Property, Plant and Equipment Gross	140,000
Property, Plant and Equipment Gross	9,972,000	$ 4,510,000
Less: accumulated depreciation	(3,579,000)	(3,747,000)
Total	$ 6,393,000	$ 763,000

Note 11 - Intangible Assets, 74

Note 11 - Intangible Assets, In-process Research and Development and Goodwill (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
RESCULA [Member]
Impairment of Intangible Assets (Excluding Goodwill)		$ 5,600,000
Impairment of Intangible Assets (Excluding Goodwill)	$ 0
Amortization of Intangible Assets	$ 3,700,000	$ 636,000	$ 1,000,000

Note 11 - Intangible Assets by

Note 11 - Intangible Assets by Major Class (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Patent and License Rights [Member]
Amortized intangible assets
Amortized intangible assets, weighted average life	6 years	7 years
Amortized intangible assets, carrying amount	$ 10,513,000	$ 10,513,000
Manufacturing Know How [Member]
Amortized intangible assets
Amortized intangible assets, weighted average life	6 years 120 days
Amortized intangible assets, carrying amount	$ 134,600,000
Accumulated amortization	(8,463,000)	$ (4,711,000)
Impairment losses	(5,651,000)	$ (5,651,000)
Intangibles, Foreign currency translation adjustment	(684,000)
Total amortized intangible assets	130,315,000	$ 151,000
Unamortized intangible assets
In-process research & development	6,171,000
Goodwill	60,937,000	$ 0
Total unamortized intangible assets	67,108,000
Total intangible assets	$ 197,423,000	$ 151,000

Note 11 - Changes in Intangible

Note 11 - Changes in Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets [Member]
Intangibles, Balance	$ 151,000	$ 6,438,000
Intangibles, Amortization	(3,752,000)	(636,000)
Intangibles, Impairment losses		(5,651,000)
Intangibles, Balance	130,315,000	151,000	$ 6,438,000
Intangibles, Additions	134,600,000
Intangibles, Foreign currency translation adjustment	(684,000)
In Process Research and Development [Member]
Intangibles, Balance	0	0
Intangibles, Balance	6,171,000	0	0
Intangibles, Additions	6,200,000
Intangibles, Foreign currency translation adjustment	(29,000)
Goodwill, Balance	0	0
Intangibles, Amortization	(3,700,000)	(636,000)	(1,000,000)
Intangibles, Impairment losses	0
Goodwill, Balance	60,937,000	$ 0	$ 0
Goodwill, Additions	61,228,000
Intangibles, Foreign currency translation adjustment	(684,000)
Goodwill, Foreign currency translation adjustment	$ (291,000)

Note 11 - Amortization of Intan

Note 11 - Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 22,689
2,017	22,689
2,018	22,689
2,019	22,689
2,020	$ 22,689

Note 12 - Summary of Accrued Ex

Note 12 - Summary of Accrued Expenses (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Research and development costs	$ 3,843,000	$ 3,537,000
Employee compensation	4,860,000	3,459,000
Restructuring Reserve	851,000	0
Selling and marketing costs	1,000	163,000
Legal service fees	428,000	612,000
Other accrued expenses	903,000	696,000
Total	$ 10,886,000	$ 8,467,000

Note 13 - Collaboration Oblig79

Note 13 - Collaboration Obligation (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Oct. 31, 2004
Global License Agreement [Member] | Up-front Payment Arrangement [Member] | Takeda [Member]
Deferred Revenue	$ 14,000,000	$ 14,000,000
Global License Agreement [Member] | Takeda [Member]
Development Expenses to Be Assumed		6,000,000	$ 6,000,000
Developmental Expense Reimbursement Obligation	5,600,000	6,000,000
Up-front Payment Arrangement [Member] | Takeda [Member]
Deferred Revenue	$ 2,400,000			$ 17,600,000
Takeda [Member]
Deferred Revenue
Deferred Revenue	$ 1,764,000	$ 7,169,000

Note 14 - Other Current Liabi80

Note 14 - Other Current Liabilities Summary (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Indirect taxes payable	$ 5,963,000	$ 3,075,000
Squeeze out liability for non-tendering R-Tech shareholders	7,668,000
Other current liabilities	508,000	$ 543,000
Total	$ 14,139,000	$ 3,618,000

Note 15 - Other Liabilities (De

Note 15 - Other Liabilities (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
JAPAN
Deferred Grants, Noncurrrent	$ 9,300,000
Montgomery County, Maryland [Member]
Deferred Grants, Noncurrrent	$ 300,000
SWITZERLAND | Net Income 1 [Member]
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)		$ 11,000
SWITZERLAND | Total Comprehensive Income [Member]
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)		$ 355,000
SWITZERLAND
Defined Benefit Plan Minimum Investment Return	1.75%	1.75%
Defined Benefit Plan, Funded Status of Plan	$ 949,000	$ (977,000)
Defined Benefit Plan, Assets for Plan Benefits	1,600,000	1,800,000
Defined Benefit Plan, Benefit Obligation	2,500,000	2,800,000
Pension Expense	226,000	221,000
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)		$ 366,000
Deferred Grants, Noncurrrent	9,604,000
Defined Benefit Plan, Funded Status of Plan	(948,000)	$ (977,000)
Defined Benefit Plan, Benefit Obligation	$ 2,513,000	$ 2,769,000	$ 1,708,000

Note 15 - Other Liabilities Sum

Note 15 - Other Liabilities Summary (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred Grants, Noncurrrent	$ 9,604,000
Liability for Uncertain Tax Positions, Noncurrent	3,061,000
Deferred leasehold incentive	1,715,000	$ 380,000
Defined benefit obligation	949,000	977,000
Other liabilities	414,000	579,000
Total	$ 15,743,000	$ 1,936,000

Note 15 - Reconciliation of Pro

Note 15 - Reconciliation of Projected Benefit Obligation and Fair Value of Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Projected benefit obligation at beginning of year	$ 2,769	$ 1,708
Service cost	164	191
Interest cost	28	43
Plan participants’ contributions	90	$ 165
Plan amendments	$ (39)
Actuarial loss (gain)		$ 653
Benefits paid	$ (436)	(83)
Benefits paid	436	83
Expenses Paid	(5)	(8)
Premiums Paid	(49)	(66)
Projected benefit obligation at end of year	2,513	2,769
Fair value of plan assets at beginning of year	1,787	1,342
Actual return on plan assets	42	42
Employer contribution	136	234
Fair value of plan assets at end of year	1,565	1,787
Defined Benefit Plan, Funded Status of Plan	$ (948)	$ (977)

Note 15 - Reconciliation of Amo

Note 15 - Reconciliation of Amounts Recognized in Consolidated Statements of Operations and Comprehensive Income (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (862)	$ (978)
Total amount recognized in accumulated other comprehensive income	(862)	(978)
Accumulated contributions in excess of net periodic benefit cost	(87)	1
Funded status at end of year	$ (948)	$ (977)

Note 15- Net Periodic Benefit C

Note 15- Net Periodic Benefit Cost Recognized (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Service cost	$ 164	$ 191
Interest cost	28	43
Expected return on assets	(39)	(30)
Amortization of unrecognized net loss	73	17
Net periodic pension cost	$ 226	$ 221

Note 15 - Changes in Plan Asset

Note 15 - Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
New prior service cost	$ (39)
Net loss arising during year	(2)	$ 641
Amortization or settlement of net loss	(73)	(17)
Total recognized in other comprehensive income	(114)	624
Total loss recognized in net periodic cost and other comprehensive income	$ 111	$ 845

Note 15 - Estimated Amounts to

Note 15 - Estimated Amounts to be Amortized From Accumulated Other Comprehensive Income Over the Next Year (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ 76	$ 73

Note 15 - Projected Benefit Obl

Note 15 - Projected Benefit Obligations in Excess of Plan Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Projected benefit obligation	$ 2,514	$ 2,769
Accumulated benefit obligation	2,233	2,469
Fair value of plan assets	$ 1,566	$ 1,792

Note 15 - Weighted Average Allo

Note 15 - Weighted Average Allocation of Plan Assets (Details)	Dec. 31, 2015	Dec. 31, 2014
Debt Securities [Member]
Weighted average allocation of plan assets	78.00%	79.00%
Real Estate [Member]
Weighted average allocation of plan assets	12.00%	12.00%
Other Investments 1 [Member]
Weighted average allocation of plan assets	8.00%	6.00%
Cash [Member]
Weighted average allocation of plan assets	2.00%	3.00%
Weighted average allocation of plan assets	100.00%	100.00%

Note 15 - Schedule of Assumptio

Note 15 - Schedule of Assumptions Used (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Discount or settlement rates	1.00%	2.50%
Expected long-term rates of return on assets	2.10%	2.10%
Rates of increase in compensation levels	1.50%	1.50%

Note 15 - Schedule of Expected

Note 15 - Schedule of Expected Benefit Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Discount rate	0.90%	1.00%
Rates of increase in compensation levels	1.50%	1.50%
2,016	$ 155	$ 151
2,016	7	145
2,017	12	10
2,018	17	14
2,019	23	18
2,020	28	23
2021-2025	$ 634	$ 494

Note 16 - Commitments and Con92

Note 16 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Guarantee of Indebtedness of Others [Member]
Loss Contingency, Range of Possible Loss, Maximum	$ 2.2
Loss Contingency, Estimate of Possible Loss	1.5
Operating Leases, Rent Expense	$ 1.8	$ 1.4	$ 1.5

Note 16 - Future Minimum, Non-C

Note 16 - Future Minimum, Non-Cancelable Lease Payments (Details) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 1,781
2,017	941
2,018	1,233
2,019	1,020
2,020	966
Total minimum lease payments	$ 5,941

Note 17 - Related Party Trans94

Note 17 - Related Party Transactions (Details Textual) SFr in Millions	12 Months Ended	154 Months Ended
	Dec. 31, 2010USD ($)	Oct. 20, 2015USD ($)	Dec. 31, 2015CHF (SFr)	Dec. 31, 2015USD ($)	Dec. 08, 2015	Dec. 01, 2015	Aug. 31, 2015	Dec. 31, 2014USD ($)	Mar. 31, 2013CHF (SFr)	Sep. 30, 2011USD ($)
Ueno Trust [Member] | Kuno Trust [Member] | SAG [Member]
Debt Instrument, Face Amount	$ 25,900,000
Drs. Ueno and Kuno [Member] | R-Tech [Member]
Business Acquisition, Percentage of Voting Interests Acquired			44.00%	44.00%
Drs. Ueno and Kuno [Member]
Related Party Ownership Percentage			47.00%	47.00%
R-Tech [Member]
Deferred Revenue				$ 0				$ 4,594,000
Numab [Member] | Zurcher Kantonalbank [Member]
Loans Pledged as Collateral									SFr 2.2	$ 5,000,000
Numab [Member] | Financial Guarantee [Member]
Restricted Cash and Cash Equivalents | SFr			SFr 2.2
Guaranty Liabilities				202,000				1,000,000
Numab [Member]
Loans Pledged as Collateral				2,200,000
Long-term Debt, Gross			SFr 1.5	1,500,000
Kuno Trust [Member] | Subordinated Unsecured Promissory Notes [Member] | SAG [Member]
Debt Instrument, Face Amount	$ 25,900,000
Kuno and Ueno Trust [Member] | Subordinated Unsecured Promissory Notes [Member] | SAG [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	4.00%
Kuno and Ueno Trust [Member] | Subordinated Unsecured Promissory Notes [Member] | SAG [Member]
Debt Instrument, Face Amount	$ 51,900,000
Debt Instrument, Interest Rate, Stated Percentage						4.70%
R-Tech [Member]
Business Acquisition, Percentage of Voting Interests Acquired		98.00%			2.00%		44.00%
Related Party Transaction, Amounts of Transaction		$ 9,000,000
Deferred Revenue				$ 1,764,000				7,169,000
Restricted Cash and Cash Equivalents								$ 2,400,000

Note 17 - Expenses Under Agreem

Note 17 - Expenses Under Agreements With R-Tech (Details) - R-Tech [Member] - USD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Oct. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Clinical Supplies [Member]
Expenses related to R-Tech	$ 155	$ 396	$ 827
Other Research and Development Services [Member]
Expenses related to R-Tech	347	171	194
Commercial Supplies [Member]
Expenses related to R-Tech	21,415	15,776	14,902
Expenses related to R-Tech	$ 21,917	$ 16,343	$ 15,923

Note 17 - Deferred Revenues Und

Note 17 - Deferred Revenues Under the Company's Agreements With R-Tech (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
R-Tech [Member]
Deferred revenue, current		$ 453,000
Deferred Revenue, Noncurrent		4,141,000
	$ 0	4,594,000
Deferred revenue, current	676,000	2,051,000
Deferred Revenue, Noncurrent	1,088,000	5,118,000
	$ 1,764,000	$ 7,169,000

Note 18 - Notes Payable (Detail

Note 18 - Notes Payable (Details Textual) - Jeffries Financing LLC [Member] - USD ($) $ in Thousands	Oct. 16, 2015	Dec. 31, 2015
Term Loans [Member] | Adjusted Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	7.25%
Debt Instrument, Variable Rate, Floor	1.00%
Term Loans [Member] | Adjusted Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	6.25%
Debt Instrument, Variable Rate, Floor	2.00%
Term Loans [Member]
Debt Instrument, Face Amount	$ 250,000
Debt Instrument, Periodic Payment	6,250
Debt Instrument, Restricted Cash Collateral Account	$ 25,000
From December 31, 2015 Through December 31, 2016 [Member]
Term Loan, Total Leverage Ratio	3.25
From January 1, 2017 Through December 31, 2017 [Member]
Term Loan, Total Leverage Ratio	2.4
From January 1, 2018 Through December 31, 2018 [Member]
Term Loan, Total Leverage Ratio	1.6
From January 1, 2019 Through December 31, 2019 [Member]
Term Loan, Total Leverage Ratio	0.8
Term Loan, Early Payment Penalty Percentage in Year Thereafter	0.00%
Term Loan, Maximum Incremental Amount	$ 25,000
Term Loan, Covenant Threshold	35,000
Term Loan, Ability to Repay, Incremental Amount, Minimum	$ 1,000
Term Loan, Early Payment Penalty Percentage in Year One	2.00%
Term Loan, Early Payment Penalty Percentage in Year Two	1.00%
Term Loan Covenant, Material Assets Disposed		$ 2,000
Term Loan Covenant, Investments and Loans		$ 15,000

Note 18 - Maturities of Notes P

Note 18 - Maturities of Notes Payable (Details) - Term Loans [Member] $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 42,582
2,017	25,000
2,018	25,000
2,019	25,000
2,020	$ 25,000

Note 19 - Collaboration and L99

Note 19 - Collaboration and License Agreements (Details Textual)	1 Months Ended						3 Months Ended		12 Months Ended				135 Months Ended
	Jun. 30, 2015USD ($)	May. 31, 2015USD ($)	Mar. 31, 2012	Apr. 29, 2008USD ($)	Jun. 30, 2007USD ($)	Oct. 31, 2004USD ($)	Dec. 31, 2014USD ($)	Jun. 30, 2013USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2006USD ($)	Dec. 31, 2015USD ($)	Oct. 31, 2014USD ($)
Up-front Payment Arrangement [Member] | Collaboration Revenue [Member]
Deferred Revenue, Revenue Recognized									$ 147,000	$ 147,000	$ 147,000
Up-front Payment Arrangement [Member] | Global License Agreement [Member] | Takeda [Member]
Deferred Revenue							$ 14,000,000		14,000,000	14,000,000			$ 14,000,000
Up-front Payment Arrangement [Member] | Takeda [Member]
Revenue Recognition, Milestone Method, Revenue Recognized													20,000,000
Deferred Revenue						$ 17,600,000			2,400,000				2,400,000
Up Front Fee And Milestone Payment Arrangement [Member] | Takeda [Member]
Revenue Recognition, Milestone Method, Revenue Recognized													160,000,000
Up Front Fee And Milestone Payment Arrangement [Member] | Mylan [Member]
Revenue Recognition, Milestone Method, Revenue Recognized									37,500,000
Milestone Payment Arrangement [Member] | Takeda [Member]
Revenue Recognition, Milestone Method, Revenue Recognized								$ 10,000,000
Development Milestone [Member] | Takeda [Member]
Deferred Revenue						50,000,000
Development Milestone [Member] | Mylan [Member]
Revenue Recognition, Milestone Method, Revenue Recognized									5,000,000	2,500,000
Reimbursement of Research and Development Expenses [Member] | Takeda [Member]
Deferred Revenue, Noncurrent						30,000,000
Research and Development Expense [Member] | Takeda [Member]
Revenue Recognition, Milestone Method, Revenue Recognized				$ 50,000,000
Global License Agreement [Member] | Takeda [Member]
Sales Revenue, Goods, Net									0	0
Revenue Recognition, Milestone Method, Revenue Recognized							14,000,000
Contingent Commerical Milestone Payments														$ 35,000,000
Development Expenses to Be Assumed							6,000,000			6,000,000				$ 6,000,000
Licenses Revenue							8,000,000
Contractual Obligation							6,000,000			6,000,000
China Gloria Agreement [Member] | Gloria [Member]
Revenue Recognition, Milestone Method, Revenue Recognized	$ 500,000	$ 1,000,000
Contingent Commerical Milestone Payments									$ 1,500,000				$ 1,500,000
Agreement Renewal Period									3 years
Agreement Termination Period									1 year
Japan Santen Agreement [Member] | Santen [Member]
Sales Revenue, Goods, Net									$ 1,500,000
Agreement Renewal Period			1 year
Agreement Termination Period			330 days
Takeda [Member] | Maximum [Member] | For Each Additional Indication [Member]
Funded Development Costs Counterparty Obligation, Amount												$ 50,000,000
Takeda [Member] | Maximum [Member] | For Each New Formulation [Member]
Funded Development Costs Counterparty Obligation, Amount												$ 20,000,000
Takeda [Member]
Deferred Revenue, Revenue Recognized										3,360,000	29,453,000
Sales Revenue, Goods, Net									$ 10,300,000
Deferred Revenue
Royalty Revenue									$ 74,000,000	62,800,000	52,100,000
Initial Funded Development Costs, Amount						30,000,000
Entity Funded Development Costs						20,000,000
Collaborative Funded Development Costs, Minimum						$ 50,000,000
Contracts Revenue					$ 30,000,000
Number of Studies in Joint Commercialization												3
Funding Labeling Studies by Other, Percentage												70.00%
Company Funded Labeling Studies, Percentage												30.00%
Co-promotion Revenue									0	3,400,000	61,000
Mylan [Member]
Sales Revenue, Goods, Net									53,900,000	32,100,000
Sales Revenue, Goods, Net									66,276,000	33,252,000	16,425,000
Revenue Recognition, Milestone Method, Revenue Recognized										8,000,000
Deferred Revenue							7,169,000		1,764,000	7,169,000			$ 1,764,000
Royalty Revenue									74,138,000	62,775,000	52,100,000
Deferred Revenue, Noncurrent							$ 5,118,000		$ 1,088,000	5,118,000			$ 1,088,000
Co-promotion Revenue										$ 3,360,000	$ 61,000

Note 19 - Cash Streams and Rela

Note 19 - Cash Streams and Related Revenue Recognized or Deferred Under the North American Takeda Agreement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Product Royalty Revenue [Member] | Takeda [Member]
Cash Received	$ 405,410,000
Deferred Revenue, Revenue Recognized	74,000,000	$ 62,775,000	$ 291,427,000
Accounts Receivable	$ 22,792,000
Deferred Revenue
Product Sales Revenue [Member] | Takeda [Member]
Cash Received	$ 996,000
Deferred Revenue, Revenue Recognized	10,311,000
Accounts Receivable	$ 9,315,000
Deferred Revenue
Research and Development Revenue [Member] | Takeda [Member] | Up Front Payment Remainder [Member]
Cash Received	$ 17,624,000
Deferred Revenue, Revenue Recognized			$ 17,624,000
Accounts Receivable
Deferred Revenue
Research and Development Revenue [Member] | Takeda [Member] | Development Milestone [Member]
Cash Received	$ 140,000,000
Deferred Revenue, Revenue Recognized			140,000,000
Accounts Receivable
Deferred Revenue
Research and Development Revenue [Member] | Takeda [Member] | Reimbursement of Research and Development Expenses [Member]
Cash Received	$ 131,432,000
Deferred Revenue, Revenue Recognized	10,164,000	$ 7,221,000	116,805,000
Accounts Receivable	$ 2,758,000
Deferred Revenue
Research and Development Revenue [Member] | Takeda [Member]
Cash Received	$ 289,056,000
Deferred Revenue, Revenue Recognized	10,164,000	$ 7,221,000	$ 274,429,000
Accounts Receivable	$ 2,758,000
Deferred Revenue
Collaboration Revenue [Member] | Takeda [Member] | Manufacturing Supply Agreements [Member]
Cash Received	$ 2,337,000
Deferred Revenue, Revenue Recognized	$ 2,337,000
Accounts Receivable
Deferred Revenue
Collaboration Revenue [Member] | Takeda [Member] | Up-front Payment Arrangement [Member]
Cash Received	$ 2,376,000
Deferred Revenue, Revenue Recognized	$ 147,000	$ 147,000	$ 1,346,000
Accounts Receivable
Deferred Revenue	$ 736,000
Collaboration Revenue [Member] | Takeda [Member]
Cash Received	4,713,000
Deferred Revenue, Revenue Recognized	$ 2,484,000	147,000	1,346,000
Accounts Receivable
Deferred Revenue	$ 736,000
Takeda [Member] | Up-front Payment Arrangement [Member]
Deferred Revenue	2,400,000
Takeda [Member]
Cash Received	$ 32,813,000
Deferred Revenue, Revenue Recognized		3,360,000	$ 29,453,000
Accounts Receivable
Deferred Revenue
Deferred Revenue	$ 1,764,000	$ 7,169,000

Note 19 - Cash Streams and R101

Note 19 - Cash Streams and Related Revenue Recognized or Deferred Under the Japan Mylan Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Mylan [Member] | Collaboration Revenue [Member] | Up-front Payment Arrangement [Member]
Cash Received	$ 846
Deferred Revenue, Revenue Recognized	$ 34	$ 39	$ 241
Accounts Receivable
Foreign Currency Effects	$ 116
Deferred Revenue	416
Mylan [Member] | Research and Development Revenue [Member] | Up Front Payment Remainder [Member]
Cash Received	$ 9,154
Deferred Revenue, Revenue Recognized			9,302
Accounts Receivable
Foreign Currency Effects	$ (148)
Deferred Revenue
Mylan [Member] | Research and Development Revenue [Member] | Development Milestone [Member]
Cash Received	$ 27,500
Deferred Revenue, Revenue Recognized	5,000		27,755
Accounts Receivable	5,000
Foreign Currency Effects	$ (255)
Deferred Revenue
Mylan [Member] | Research and Development Revenue [Member]
Cash Received	$ 36,654
Deferred Revenue, Revenue Recognized	5,000		37,057
Accounts Receivable	5,000
Foreign Currency Effects	$ (403)
Deferred Revenue
Mylan [Member] | Product Sales Revenue [Member]
Cash Received	$ 96,937
Deferred Revenue, Revenue Recognized	48,908	$ 32,088	$ 20,830
Accounts Receivable	4,958
Foreign Currency Effects	$ 69
Deferred Revenue
Deferred Revenue	$ 1,764	$ 7,169

Note 20 - Stockholders' Equi102

Note 20 - Stockholders' Equity (Details Textual)	Oct. 20, 2015USD ($)$ / sharesshares	Jan. 19, 2015	Jan. 31, 2013USD ($)	Aug. 31, 2005$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Aug. 31, 2015¥ / shares	Jan. 02, 2015shares	Jan. 02, 2014shares	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)	Dec. 31, 2008USD ($)	Dec. 31, 2006shares	Dec. 31, 2003shares
Stock Incentive Plan 2006 [Member] | Common Class A [Member]
Annual Increase in Number of Shares, Issuance					500,000				0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized														8,500,000
Stock Incentive Plan 2006 [Member]
Annual Increase in Number of Shares, Issuance										0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,321,634
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares					$ 15.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number					1,763,116
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					6 years 324 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					693,077
Proceeds from Stock Options Exercised | $					$ 4,100,000	$ 2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					2,083,077
Share Based Compensation, Arrangement by Share Based Payment Award, Increase in Common Stock Available for Issuance as Percentage of Aggregate Number of Shares Outstanding					5.00%
Amended 2001 Plan [Member] | Common Class A [Member] | Non-Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized															8,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				510,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 5.85
Amended 2001 Plan [Member] | Non-Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number					0	255,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					0 years	91 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					127,500	155,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $					$ 1,000,000	$ 300,000
Proceeds from Stock Options Exercised | $					$ 700,000	$ 900,000
Amended 2001 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number					37,400	113,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					124 days	339 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					76,500	6,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $					$ 600,000	$ 28,000
Proceeds from Stock Options Exercised | $					$ 800,000	$ 68,000
Amended 2001 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number					37,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					124 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					76,500
2006 Employee Stock Purchase Plan [Member] | Common Class A [Member]
Common Stock, Capital Shares Reserved for Future Issuance														4,250,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans					9,085	5,853	3,625
Stock Issued During Period, Value, Employee Stock Purchase Plan | $					$ 128,000	$ 35,000	$ 24,000
2006 Employee Stock Purchase Plan [Member]
Share Based Compensation, Percentage of Compensation to Purchase Common Stock					10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		85.00%
Common Class A [Member] | Cantor Sales Agreement [Member] | Cantor Fitzgerald & Co. [Member]
Common Stock Maximum Aggregate Sales Price, Sales Agreement | $			$ 20,000,000
Common Class A [Member] | Cantor Sales Agreement [Member]
Stock Issued During Period, Shares, New Issues						538,521
Proceeds from Issuance of Common Stock | $						$ 5,500,000
Common Class A [Member] | R-Tech [Member]
Business Acquisition, Share Price | $ / shares	$ 17.68
Common Class A [Member]
Stock Repurchase Program, Authorized Amount | $											$ 5,000,000	$ 2,000,000	$ 10,000,000
Stock Repurchased During Period, Shares							67,762
Stock Repurchased During Period, Value | $							$ 336,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate					10.00%	10.00%	10.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate					30.94%	30.94%	30.94%
Cantor Sales Agreement [Member] | Cantor Fitzgerald & Co. [Member]
Sales Agreement, Commission Rate as a Percentage of Gross Sales			3.00%
R-Tech [Member]
Treasury Stock, Shares, Acquired	2,485,150
Treasury Stock, Value, Acquired, Cost Method | $	$ 44,000,000
Business Acquisition, Share Price | ¥ / shares								¥ 1,400
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $					$ 9,800,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					2 years 292 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					200,000
Time-based Accelerated Stock Options [member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					450,000
Allocated Share-based Compensation Expense | $					$ 1,000,000
Time-based Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,321,634
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Class A Common Stock, Number of Votes per Share					1
Proceeds from Issuance of Common Stock | $						$ 5,326,000	$ 5,281,000
Treasury Stock, Value, Acquired, Cost Method | $					$ 43,956,000		336,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					693,077	618,377
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $					$ 8,600,000	$ 3,000,000
Proceeds from Stock Options Exercised | $					5,623,000	3,789,000	2,337,000
Allocated Share-based Compensation Expense | $					$ 7,349,000	$ 2,287,000	$ 1,744,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares					$ 15.18	$ 7.68	$ 7.36
Stock Issued During Period, Value, Employee Stock Purchase Plan | $					$ 128,000	$ 36,000	$ 25,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation | $					$ 2,475,000	$ 113,000	$ 213,000

Note 20 - Option Valuation Assu

Note 20 - Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Minimum [Member]
Expected volatility	54.00%	70.00%	65.00%
Risk-free interest rate	1.34%	1.63%	1.23%
Expected term (in years)	5 years 102 days	5 years 102 days	5 years 182 days
Maximum [Member]
Expected volatility	70.00%	72.00%	75.00%
Risk-free interest rate	1.93%	2.01%	1.40%
Expected term (in years)	6 years 91 days	6 years 91 days	6 years 91 days
Expected dividend yield	0.00%	0.00%	0.00%

Note 20 - Stock-based Compensat

Note 20 - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Research and Development Expense [Member]
Allocated share-based expense	$ 2,165	$ 349	$ 293
General and Administrative Expense [Member]
Allocated share-based expense	5,053	1,816	1,260
Selling and Marketing Expense [Member]
Allocated share-based expense	131	122	191
Allocated share-based expense	$ 7,349	$ 2,287	$ 1,744

Note 20 - Stock Option Activity

Note 20 - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Non Employee Stock Plan 2001 [Member]
Options outstanding (in shares)	255,000
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.85
Options exercised (in shares)	(127,500)
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.85
Options expired (in shares)	(127,500)
Options Expired, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.85
Options outstanding (in shares)		255,000
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)		$ 5.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Options Exercisable, Weighted Average Exercise Price Per Share (in dollars per share)
Options vested and expected to vest, December 31, 2015 (in shares)
Options vested and expected to vest, December 31, 2015 (in dollars per share)
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.85
Amended 2001 Plan [Member]
Options outstanding (in shares)	113,900
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10
Options exercised (in shares)	(76,500)
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10
Options outstanding (in shares)	37,400	113,900
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10	$ 10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	37,400
Options Exercisable, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10
Options vested and expected to vest, December 31, 2015 (in shares)	37,400
Options vested and expected to vest, December 31, 2015 (in dollars per share)	$ 10
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10
Options Outstanding, Weighted Average Remaining Contractual Term	124 days
Options Outstanding, Aggregate Intrinsic Value	$ 272,646
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	124 days
Options Exercisable, Aggregate Intrinsic Value	$ 272,646
Options vested and expected to vest, December 31, 2015	124 days
Options vested and expected to vest, December 31, 2015	$ 272,646
Stock Incentive Plan 2006 [Member]
Options outstanding (in shares)	4,021,491
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 6.93
Options exercised (in shares)	(693,077)
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.93
Options expired (in shares)	(3,924)
Options Expired, Weighted Average Exercise Price Per Share (in dollars per share)	$ 4.09
Options outstanding (in shares)	4,440,608	4,021,491
Options Outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 9.37	$ 6.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,763,116
Options Exercisable, Weighted Average Exercise Price Per Share (in dollars per share)	$ 7.07
Options vested and expected to vest, December 31, 2015 (in shares)	3,581,991
Options vested and expected to vest, December 31, 2015 (in dollars per share)	$ 8.99
Options Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 5.93
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 83 days
Options Outstanding, Aggregate Intrinsic Value	$ 35,461,431
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 324 days
Options Exercisable, Aggregate Intrinsic Value	$ 18,019,310
Options vested and expected to vest, December 31, 2015	8 years 7 days
Options vested and expected to vest, December 31, 2015	$ 29,896,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,321,634
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 15.18
Options Forfeited (in shares)	(205,516)
Options Forfeited, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10.45
Options exercised (in shares)	(693,077)	(618,377)

Note 20 - Changes in Accumulate

Note 20 - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	$ 15,208	$ 15,559	$ 16,126
Other comprehensive income before reclassifications	$ (965)	$ (351)	$ (567)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ 14,243	$ 15,208	$ 15,559
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Balance	35	42	40
Other comprehensive income before reclassifications	$ 7	$ (7)	$ 2
Amounts reclassified from accumulated other comprehensive loss
Balance	$ 42	$ 35	$ 42
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(978)
Other comprehensive income before reclassifications	$ 105	$ (978)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ (873)	$ (978)
Balance	14,265	15,601	$ 16,166
Other comprehensive income before reclassifications	$ (853)	$ (1,336)	$ (565)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ 13,412	$ 14,265	$ 15,601

Note 21 - Income Taxes (Details

Note 21 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Domestic Tax Authority [Member] | Earliest Tax Year [Member]
Income Tax Examination, Year under Examination	2,009
Domestic Tax Authority [Member] | Latest Tax Year [Member]
Income Tax Examination, Year under Examination	2,011
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 0	$ 0
Foreign Tax Authority [Member]
Operating Loss Carryforwards	2,800,000	5,900,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,000,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 1,800,000
Earliest Tax Year [Member]
Open Tax Year	2,011
Latest Tax Year [Member]
Open Tax Year	2,015
Deferred Tax Assets, Valuation Allowance	$ 2,277,000	2,132,000
Unrecognized Tax Benefits, Including Interest and Penalties	3,100,000	$ 800,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,700,000
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 1,300,000

Note 21 - Income Before Income

Note 21 - Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
U.S.	$ 14,685	$ 18,005	$ 9,175
Foreign	28,990	9,128	1,768
	$ 43,675	$ 27,133	$ 10,943

Note 21 - Provision for Income

Note 21 - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current tax provision (benefit):
U.S. Federal	$ 15,678	$ 11,319	$ 5,198
U.S. State	1,810	1,351	1,008
Foreign	2,709	793	(582)
Total current tax provision	20,197	13,463	5,624
Deferred provision (benefit):
U.S. Federal	(6,375)	(172)	(1,783)
U.S. State	(899)	(16)	(279)
Foreign	(2,619)	730	366
Total deferred provision (benefit)	(9,893)	542	(1,696)
Total income tax provision	$ 10,304	$ 14,005	$ 3,928

Note 21 - Deferred Tax Assets (

Note 21 - Deferred Tax Assets (Liabilities), Net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Foreign net operating loss carry-forwards	$ 716	$ 1,409
State net operating loss carry-forwards	2	$ 3
Tax credit carry-forwards	976
Deferred revenue	446	$ 1,803
Accrued expenses	1,450	734
Tax benefits on stock options	3,288	$ 2,063
Research and development credits	$ 1,759
Inventory		$ 615
Property and equipment		15
Other	$ 3,775	207
Gross deferred tax assets	12,412	6,849
Deferred tax liabilities:
Property and equipment	(654)	$ (122)
Inventory	(3,990)
Investments	(13,963)
Intangibles	(44,025)	$ (4,368)
Gross deferred tax liabilities	(62,632)	(4,490)
Less: valuation allowance	(2,277)	(2,132)
Net deferred tax assets (liabilities)	$ (52,497)
Net deferred tax assets (liabilities)		$ 227

Note 21 - Income Taxes on the F

Note 21 - Income Taxes on the Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Federal tax provision (benefit)	35.00%	35.00%	35.00%
State taxes, net of federal tax benefit	0.90%	2.10%	4.90%
Foreign tax rate differential	(16.80%)	0.00%	0.00%
Changes in valuation allowance	0.50%	1.40%	(21.60%)
Nondeductible expenses	2.30%	1.70%	1.30%
Stock based compensation	0.60%	(0.10%)	(2.80%)
Impact of intangible transfer	0.70%	5.80%	7.30%
Impact of uncertain tax positions	1.80%	(0.20%)	(0.10%)
Adjustment to deferred tax asset	(1.60%)	0.50%	11.10%
Impact of foreign operations	0.00%	(3.70%)	0.30%
Subpart F income, net of FTC	2.30%	9.10%	0.00%
Change in tax rates	0.00%	0.00%	0.60%
Loan forgiveness	(2.30%)	0.00%	0.00%
Japanese R&D credit	(1.60%)	0.00%	0.00%
Changes in other tax matters	1.80%	0.00%	(0.10%)
	23.60%	51.60%	35.90%

Note 21 - Unrecognized Tax Bene

Note 21 - Unrecognized Tax Benefits Excluding Interest and Penalties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Balance	$ 712	$ 550	$ 979
Increases for tax positions taken during prior periods	452	$ (91)	4
Decreases in unrecognized tax benefits related to taxing authority correspondence	(280)		(467)
Increases for tax positions taken during current period	2,108	$ 253	34
Balance	$ 2,992	$ 712	$ 550

Note 22 - Quarterly Financia113

Note 22 - Quarterly Financial Date Summary (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Total	$ 55,368	$ 33,448	$ 34,884	$ 29,480	$ 37,757	$ 31,463	$ 24,069	$ 22,161	$ 153,180	$ 115,450	$ 89,594
Income from operations	11,568	11,657	11,580	9,654	17,048	3,643	3,811	2,729	44,459	27,231	9,196
Net income	$ 10,151	$ 7,236	$ 9,576	$ 6,408	$ 9,283	$ 1,480	$ 1,610	$ 755	$ 33,371	$ 13,128	$ 7,015
Net income per share:
Basic net income per share (in dollars per share)	$ 0.24	$ 0.16	$ 0.21	$ 0.14	$ 0.21	$ 0.03	$ 0.04	$ 0.02	$ 0.76	$ 0.30	$ 0.17
Diluted net income per share (in dollars per share)	$ 0.23	$ 0.16	$ 0.21	$ 0.14	$ 0.21	$ 0.03	$ 0.04	$ 0.02	$ 0.73	$ 0.29	$ 0.16
Total	$ 55,368	$ 33,448	$ 34,884	$ 29,480	$ 37,757	$ 31,463	$ 24,069	$ 22,161	$ 153,180	$ 115,450	$ 89,594
Income from operations	11,568	11,657	11,580	9,654	17,048	3,643	3,811	2,729	44,459	27,231	9,196
Net income	$ 10,151	$ 7,236	$ 9,576	$ 6,408	$ 9,283	$ 1,480	$ 1,610	$ 755	$ 33,371	$ 13,128	$ 7,015

Note 23 - Subsequent Events (De

Note 23 - Subsequent Events (Details Textual) - Subsequent Event [Member] - CPP [Member] $ in Millions	Jan. 11, 2016USD ($)	Jan. 11, 2016USD ($)
Collaboration Agreement, Amount of Investment	$ 5	$ 5
Collaboration Agreement, Amount of Equity Investment	5	$ 5
Option Fee, Maximum	$ 7.5
Number of Tranches	2	2
Payment of Option Fee		$ 3
Maximum Aggregate License Fees and Milestone Payments	$ 190

Schedule II - Valuation and 115

Schedule II - Valuation and Qualifying Accounts (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (1,000,000)	$ 381,000	$ (2,400,000)
Valuation Allowances and Reserves, Charged to Cost and Expense	$ 1,200,000

Schedule II - Valuation and 116

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)		12 Months Ended
		Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Balance at Beginning of Year		$ 25,000		$ 440,000		$ 280,000
Additions Charged to Costs and Expenses		29,000		364,000	[1]	160,000	[1]
Balance at End of Year		54,000		25,000		440,000
Deductions	[2]			(779,000)
Valuation Allowance of Deferred Tax Assets [Member]
Balance at Beginning of Year		2,132,000		1,751,000		4,142,000
Additions Charged to Costs and Expenses		1,177,000	[3]	381,000	[4]
Balance at End of Year		2,277,000		$ 2,132,000		1,751,000
Deductions	[5]	(1,032,000)				$ (2,391,000)
Additions Charged to Costs and Expenses		$ 1,200,000
[1]	In 2013 and 2014, the increase in allowance for doubtful accounts is associated with certain disputed Takeda invoices.
[2]	In 2014 the deduction from allowance for doubtful accounts resulted from a charge-off of certain disputed Takeda invoices.
[3]	In 2015, the net increase in the valuation allowance of $1.2 million was a result of the accrual of tax credit carryforwards that are expected to expire prior to utilization.
[4]	The net increase of $381,000 was primarily due to the additional NOL's in foreign jurisdictions where management believes it is more likely than not a portion of the NOL balance will expire prior to utilization.
[5]	In 2013 and 2015, the net decrease in valuation allowance for deferred tax assets of $2.4 million and $1.0 million, respectively, was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent in 2013 for anticipated liquidation.